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ABSTRACT
Characterization of a Dexamethasone-Immunosuppressed C57BL/6N
Mouse Model for Chronic Cryptosporidiosis
by
Edward G. Martin, Master of Science
Utah State University, 1993
Major Professor: Dr. Mark C. Healey
Department: Animal, Dairy and Veterinary Sciences

Cryptosporidium parvum is a coccidian protozoan that colonizes epithelial cells
lining respiratory and digestive tracts of animals and humans. Cryptosporidiosis is a
well-recognized zoonotic disease infecting primarily neonates and immunocompromised
hosts, including human immunodeficiency virus-infected patients. Clinical disease is
manifested as a chronic diarrheal illness that is self-limiting in immunocompetent hosts
and prolonged and often life-threatening in hosts with compromised immune systems.
The lack of a suitable small animal model for screening anti-cryptosporidial drugs and for
examining the pathogenicity and immunobiology of chronic cryptosporidiosis was the
impetus for this research effort.
The objectives of the present study were three-fold:

to characterize chronic

Cryptosporidium parvum infections in dexamethasone-immunosuppressed mice; evaluate
the effects of Cryptosporidium parvum and dexamethasone on B and T lymphocyte
proliferation; and determine the effects of the immunomodulator dehydroepiandrosterone
on oocyst shedding intensities of mice infected with Cryptosporidium parvum.
Adult C57BL/6N mice were immunosuppressed with the synthetic glucocorticoid
dexamethasone, then infected with Cryptosporidium parvum (106 oocysts/mouse) and

X

investigated for their ability to sustain a four-month chronic infection. Dexamethasone
was administered intraperitoneally (125J.1glmouse/day) or orally (8J.lglml) in the drinking
water ad libitum. Infection chronicity was characterized by evaluating mouse monality,
oocyst excretion in the feces, tissue distribution of the parasite, and parasite-induced
pathology.
A progressive infection with Cryptosporidium parvum occurred in mice
immunosuppressed intraperitoneally and orally as long as dexamethsone was
administered. Mice receiving dexamethasone given intraperitoneally had a shoner
prepatent period and a more consistent, although cyclic, oocyst shedding pattern when
compared with mice given dexamethasone orally. Mice given dexamethasone orally
exhibited a delayed prepatent period, with a steady increase in oocyst shedding. All mice
receiving dexamethasone orally died within three months following oocyst inoculation.
Clinical signs included dehydration, icterus, and reduction in spleen and body weights.
Clinical signs were more abrupt in mice receiving oral dexamethasone.
Parasite colonization involved the entire intestinal tract, including the pyloric ring
and Peyer's patches, but was the heaviest in the terminal ileum. Parasites were present in
the lungs, gallbladder, and pancreatic ducts. Pathologic abnormalities were isolated to
the terminal small intestine and included blunting and fusion of intestinal villi and crypt
hyperplasia.

Cryptosporidium parvum and dexamethasone administered in vivo reduced B and T
Iymphocyte responses to the mitogens lipopolysaccharide and concanavalin A.
Dehydroepiandrosterone and dehydroepiandrosterone-sulfate resulted in no
significant reductions in cryptosporidial activity as determined by oocyst shedding in the
fece s.

(100 pages)

INTRODUCTION
Background. Cryptosporidium parvum is not a "new" organism. Ernest E.

Tyzzer ftrst described C. parvum in 1912 (116) and at the time, the intestinal protozoan
was regarded as a benign commensal. In the early 1970's, C. parvum was recognized as
a significant pathogen for calves. Since that time, the parasite has been isolated from
many species of wild and domestic animals (39). Consequently, cryptosporidiosis
became more fully appreciated as a cause of great economic loss to agriculture almost half
a century following its original description (117). During the last 18 years, C. parvum
infections have been recognized as severe, life·threatening illnesses of people (44).
Cryptosporictiosis has been reported worldwide in more than 20 countries on 6 continents
(44). Today, C. parvum is thought to be one of the most significant enteropathogens in
under-develcped ::oan:rics. The highest pn:valencc of the disease appears to be i.1
malnourished children, patients receiving chemotherapy, and inctividuals with AIDS (39).
Detection of C. parvum in patients with AIDS heightened physician awareness of the
pathogenic potential of the parasite in immunocompetent and immunocompromised hosts.
Between 1976 and 1982, fewer than 10 reports of human cryptosporictiosis had been
documented (44). Since that time, an explosion of publications has attracted the
attentions of scientists worldwide. Thus, tremendous interest has been generated
regarding cryptosporidiosis and the thrust of experimental research has been in the
development of in vitro and in vivo models for screening anti-cryptosporidial agents (26,
39, 44, 117).
More success has been experienced with the development of in vivo models as
opposed to in vitro systems. A variety of laboratory animals have been examined for
their use in studying C. parvum infection and valuable information has been gleaned from
these experiments (5, 15, 19, 28, 41 , 52, 65, 74, 75, 79, 94, 97, 98, 104, 122, 123).
In order to establish a chronic C. parvum infection, the animal model must be
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immunocompromised, either genetically or by exogenous immunosuppression. It is also
important that the model possess an immune system comparable to hosts that readily
contract and succumb to C. parvum infection. These requirements for a model improve
both its reliability and utility in determining the immunobiology and pathophysiology
involved in developing resistance to cryptosporidiosis.
Neonates were initially explored as potential animal models for cryptosporidiosis
because of their susceptibility to C. parvum without the use of exogenous
immu nosuppression. To date, the most commonly used small animal model for
cryptosporidiosis is the neonatal mouse (28, 119). The use of neonates has been limited
because they do not provide sufficient time for screening drugs before they clear the
infection.
A number of genetically immunodeficient animals have also been investigated as
possible models for cryptosporidial infection (74, 75, 122). This type of animal is
susceptible to C. parvum and can maintain a chronic infection. Information regarding
parasite migration in host tissues during a chronic infection has been gleaned using
immunodeficient models (75). Because of their genetic immunodeficiency, it is difficult
to accurately determine the immunologic response associated with the development of
resistance to an infection.

The housing demands and high cost of a genetically

immunodeficient animal decrease its practical use when compared with other models.
Thus, the use of immunodeficient animals has been limited.
Finally, animals requiring exogenous immunosuppression have also been examined
for studying cryptosporidiosis (15, 94, 97, 98, 123). This type of animal model is
useful for studying acute and chronic phases of the infection and can be used to assess
the immunologic response to infection. However, a readily available small animal model
for examining the chronic nature of cryptosporidiosis as seen in AIDS and other
immunocompromised patients is still lacking. Evidence of genetic preference of C.
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parvum for its host and the presence of species susceptibility to the parasite are important
fac tors to consider when selecting a reliable laboratory animal model.

Statement of the Problem.

To date , there is no known effective

chemotherapeutic agent for animals or humans infected with C. parvum. In fact ,
cryptosporidiosis is the only known opportunistic infection in AIDS patients for which
there is no effective treatment The two main factors limiting the development of effective
anti-cryptosporidial drugs is the lack of a reliable in vitro cell cultivation system and the
lack of an easily adaptable laboratory animal model for screening drug efficacy. It is the
laner which is the impetus for the present research.

Purpose of this Research. The purpose of the present study was to develop
and characterize a reliable mouse model for cryptosporid.iosis and investigate the immune
parameters involved in a chronic infection. Adult C57BU6N female mice were used in
these studies because of their susceptibility to C. parvum following exogenous
immunosuppression (92). Dexamethasone (DEX), a synthetic glucocorticoid previously
described as an effective drug capable of inducing susceptibility to C. parvum in other
rodent models (92, 94, 98), was used to immunosuppress the mice. The DEX is known
to induce a state of leukocytopenia as a result of immediate and profound
lymphocytolysis in mice (20).

Objectives. Three objectives relating to the development and characterization of a
laboratory mouse model for chronic cryptosporid.iosis were identified:
I.

Characterize Cryptosporidium parvum infections in dexamethasone-

immunosuppressed mice by evaluating infection duration, tissue distribution, tissue
pathology, and parasite load.
2.

Determine the effects that Cryptosporidium parvum and dexamethasone

have on the immune status of mice (including BandT lymphocytes and spleen weights)
relative to oocyst shedding intensities .
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3.

Assess

the

therapeutic

utility

of

the

immunomodulator

dehydroepiandrosterone as a means to enhance resistance to Cryptosporidium parvum in
mice immunosuppressed with dexamethasone.
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LITERATURE REVIEW
History. In 1912, the American parasitologist, Ernest Edward Tyzzer, isolated

the coccidian parasite, Cryptosporidium parvum, from the intestinal epithelia of the
common mouse (116). During that same year, Tyzzer named C. parvum as a new
species and provided remarkable morphologic detail that has been confirmed by the use
of electron microscopy (39).

Taxonomists have found many detailed biological

characteristics that classify Cryptosporidium as one of several genera of coccidian
protozoans belonging to the phylum Apicomplexa (26). Although many species of
Cryptosporidium have been named on the basis of the host in which they were originally
described (39), recent reviews and cross transmission studies cast doubt on the validity
of most of these species. Currently, C. parvum, C. muris (another mammalian species)
and two avian spedes, C. baileyi and C. meleagridis, are accepted as valid and distinct
species. Of these species, C. parvum is unique in that it appears to be infectious to all
mammals, including humans.
Nearly half a century passed from the original description of C. parvum before
cryptosporidiosis was recognized by more than taxonomists. Large economic losses in
the early 1970's associated with severe bovine diarrhea captured the interests of
veterinarians (39). In 1976, two independent findings linked cryptosporidiosis with
morbidity in humans (77, 85). It was not until the early 1980's that the emergence of the
acquired immunodeficiency syndrome (AIDS) epidemic heightened awareness that C.
parvum was becoming an important human pathogen (26, 44, 58).
The parasite is found as an opportunistic invader of various mucosal surfaces,
especially those of the digestive and respiratory tracts in hosts with a compromised
immune system. It is also recognized as a probable extraintestinal pathogen (39). The
acute recognition of C. parvum as a potentially fatal human enteric pathogen stimulated
activity in the research community. Investigators began refining diagnostic techniques,
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defining the epidemiology, and developing anticryptosporidial drugs via in vitro and in
vivo systems in hopes of interrupting the parasite's life cycle (39, 44).
Life Cycle. The life cycle of C. parvum is representative of other coccidians in
th at it possesses both asexual and sexual stages of reproduction. Figure I identifies six
major developmental phases which have been recognized (44, 58): excystation (release
of infective spororoites); merogony (asexual multiplication) resulting in the formation of
type I and type II meronts; gametogony (gamete formation) ; fertilization yielding
immarure oocysts or zygotes; oocyst wall formation giving rise to thick-walled (80%) and
thin-walled (20%) oocysts; and sporogony (spororoite formation).
The prepatent period, from acquisition of the parasite to the demonstration of
oocysts in the feces, ranges from 5 to 28 days with a mean of 7 days (39). The timing of
appearance of specific developmental stages is not certain. Current et al. (31) has
demonstrated that spororoite-infected cell cultures developed into mature type I meronts,
type II meronts, gamonts and oocysts at 12, 24, 48, and 72 hours, respectively. The
patent period, which is defined as the duration of oocyst shedding, varies with the host.
The persistance of this parasite, especially in immunocompromised patients, is due
primarily to its ability to undergo unlimited cycles of asexual schizogony and produce
thin-walled oocysts important for initiating an auto-infection.
When sporulated oocysts from contaminated food or water are ingested by a
suitable host, they pass through the stomach and excyst in the small intestine, releasing
infective sporozoites. The process of excystation is initiated by the presence of pancreatic
enzymes, bile salts, and other reducing agents. The sporozoites invade and replicate
within the microvillous border of epithelial cells that line the digestive and respiratory
organs of the host (29, 32). As the sporozoites and merozoites penetrate epithelial cells,
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Figure 1. Diagrammatic representation of the proposed life cycle of Cryptosporidium
parvum as it occurs in experimentally infected mice. Adapted from Current (29) and
Dubey (39).

they become enveloped by host cells and eventually reside within individual
parasitophorous vacuoles. However, the developmental stages do not reside within the
cytoplasmic portion of the host cell as do most other coccidians. Thus, developmental
stages of C. parvum are confined to an intracellular-extracytoplasmic location:
intracellular because each stage is surrounded by a parasitophorous vacuole of host cell
origin ; extracytoplasmic because the parasite-containing vacuole remains at the
microvillous surface of the host epithelial cell. It is at this location that C. parvum gives
rise to the pathological lesions and clinical signs associated with this disease.

8
Pathogenesis and Clinical Signs.

The invasive parasitic stages rapidly

destroy the integrity of infected epithelial cells (118).

The respiratory tree,

gastrointestinal tract, and associated organs (pancreas, liver, and gall bladder) are
particularily susceptible to infection by C. parvum in both human and non-human hosts
(50, 75, 122). Epithelial cells lining the terminal small intestine (jejunum and ileum) are
usually most heavily colonized (77). The location of the parasite at the epithelial surface
results in a loss of nticrovilli and a decrease in the levels of digestive enzymes. This, in
turn, interferes with absorptive and other functions of the cells, leading to malabsorption
and malnutrition. Thus, it is not surprising that one of the most prontinent clinical
features associated with this disease in humans is a watery, cholera-like diarrhea .. In
rodents, diarrhea is rare because of the efficient fluid and electrolyte absorption occuring
in the cecum. Other clinical presentations include hepatitis, cholecystitis, pancreatitis,
reactive arthritis, conjunctivitis, and a variety of respiratory problems (39). These are
due undoubtedly to the parasite's proposed ability to migrate to distal sites during a
chronic infection.
At the nticroscopic level, a number of pathologic findings are characteristic for C.

parvum infection. Infected intestinal cells appear swollen and vacuolated, with more of a
cubodial or squamous cellular morphology as opposed to the normal columnar
appearance (39). Intestinal villi are blunt, shortened, and wider than normal and may be
fused with adjacent villi if the infection is heavy. Crypts appear larger than normal due to
parasite-induced hyperplasia. Inflammatory changes of the subepithelial lamina propria
include cellular infiltrations of neutrophils, plasma cells, macrophages, and lymphocytes
(29). Mesenteric lymph nodes may be swollen, and Peyer's patches appear reactive (39).

Cryptosporidiosis in Domestic Animals. Due to its broad host specificity,
C. parvum has proven to be of significant agricultural importance as a cause of neonatal
diarrhea in numerous domestic animals, in particular, calves, kids, and lambs (119).
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Numerous studies suggest that cryptosporidia are common enteropathogens of neonatal
ruminants (39, 44, 117). However, the role of C. parvum as a primary pathogen in these
hosts is not clear. Field studies have demonstrated that the parasite can cause clinical
diarrhea in the absence of other common agents normally associated with neonatal
diarrhea (39). In the United States, the average annual livestock losses attributed to
cryptosporidial infections are believed to exceed $6.2 million. Consequently, many
outbreaks of intestinal C. parvum infections have engaged the attentions of veterinarians,
particularly where farmed ruminants are involved. Despite more than a decade of
experience involving C. parvum infections in livestock, virtually all that has been
achieved is a capability for diagnosing the presence of the oocyst stage in feces,
disinfecting premises, and interrupting the spiral of infection encountered in contaminated
environments by modifying existing management procedures (3). Effective prophylactic
and therapeutic measures for controlling C. parvum infections in animals are still lacking.

Cryptosporidiosis in Humans.

The earliest documented cases of

cryptosporidiosis in humans were in 1976. A 3-year-old child and a 39-year-old college
administrator, both from farming communities, were diagnosed with C. parvum
infections associated with abdominal pain, cramping, and severe watery diarrhea (77,
85). Both patients recovered within two weeks following symptomatic treatment.
During the next several years, especially when the AIDS epidemic gave new importance
to cryptosporidiosis, several worldwide reports of human cryptosporidiosis appeared in
the literature. These findings gave researchers crucial information concerning
transmission, immunobiology, and pathophysiology of this parasite.
Humans may acquire the infective C. parvum oocysts from other persons (32),
contaminated drinking water (33, 54), and infected animals (64, 99).

Young

malnourished children are most commonly infected (44, 119), but previously unexposed
adults with intact immune systems are also susceptible to C. parvum (54, 64). Studies
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have shown that there is a link between the severity of illness and degree of immune
competence in the host (29, 32).

Cryptosporidium parvum infection in immunocompetent individuals is characterized
as a benign, self-limiting, flulike illness generally producing mild signs and symptoms of
disease. Diarrhea is the most common clinical feature of this intestinal infection. Clinical
illness in patients with intact immune systems usually resolves within 30 days, in some
cases maintaining a persistence for transmission for up to 60 days (40, 59, 112). There
have been several reports of asymptomatic human infection as well. In contrast,
immunodeficient or immunocompromised hosts, especially human immunodeficiency
virus (HIV)-infected persons, have a severe, fulminate, and frequently unremitting illness
often conoibuting to mortality. Although a cholera-like diarrhea is the most noteworthy
clinical sign, abdominal pain, nausea, fever, malaise, and respiratory manifestations of
the infection are also common. Most immunocompromised patients harboring C. parvum
in their respiratory tracts succumb to infection (39). Since the early 1980's, most of the
reported cases of human cryptosporidiosis (respiratory and intestinal) have been
associated with AIDS patients (58). Relatively few cases were diagnosed, however, until
the disease was reported to be life-threatening (44). Ultimately, clinical disease in
patients with immune deficiencies varies with their ability to reverse the
immunosuppression.

Immunological Response of the Host. Information regarding the function
of the immune response in hosts infected with C. parvum is scant. Nonetheless, the
severity of infection can range from subclinical to severe, depending upon the host's age
and immunological status.

Age-related susceptibility as well as resistance to

cryptosporidiosis has been documented (10, 29, 93). Generally, young infants and
animals with immature immune systems are more susceptible to infection. They exhibit
severe and sometimes fatal clinical disease, but with symptomatic treatment, it allows
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their immune systems to mature and they rid themselves of the infection. Adults, on the
other hand, may appear asymptomatic, demonstrate acute illness, or exhibit chronic
illness lasting months to years. Thus, distinct differences exist between the clinical
course of the disease in immunocompetent versus immunocompromised hosts. These
differences have been attributed to the immune response to the parasite.
Clinical evidence has indicated that impairment of cellular and/or humoral immunity
delays and often prevents recovery from cryptosporidiosis (29, 60, 118 ). There is still
some controversy as to which branch of the immune system plays the more significant
role in clearing the infection. Numerous scenarios predispose individuals to C. parvum
infection, including exogenous immunosuppressive agents for cancer chemotherapy,
hypo- or agammaglobulinemia, malnourishment, intercurrent viral infections, pregnancy,
and AIDS (32, 39). Specific bovine immunoglobulins (lgM, IgA, and IgG) against C.
parvum oocysts and sporozoites have been identified. Also, anti-C. parvum lgG, IgM,

IgA , and IgE have been identified in the sera of previously infected humans. Though
studies have demonstrated that sporozoites can be neutralized by antibodies, a measurable
humoral response alone does not provide sufficient protection against the disease (60).
For instance, AIDS patients produce both IgM and IgG and yet suffer from chronic
cryptosporidiosis. In contrast, studies in patients with B lymphocyte dysfunctions
(hypo- or agammaglobulinemia), but with T lymphocyte functions intact, still develop
chronic cryptosporidiosis (60). Experimental studies have demonstrated the important
role T lymphocytes play in the clearance of and resistance to cryptosporidiosis in
mammals (29, 60, 122, 123), suggesting the likelihood that a successful response to
infection involves aT lymphocyte-dependent induction of specific secretory antibody
responses (29). Thus, a protective immune respon se may require the orchestration of
specific humoral and cell-mediated immune mechanisms.
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To appropriately mimic the chronic, life-threatening nature of C. parvum infections
in AIDS and other immunocompromised patients, and to further elucidate the immune
mechanisms involved in the host's immunological response to infection, suitable in vitro
and in vivo models are essential.
In Vitro Cultivation. The lack of a simplistic, standardized in vitro cultivation
system has not only limited testing of possible therapeutics for cryptosporidiosis, but has
also limited an understanding of the host's immunological response to this parasite.
Although there is a species of Cryptosporidium (C. baileyi) that grows readily in
numerous in vitro culture systems, the mammalian species (C. parvum) is much more
selective. The latter species has been found to complete its entire life cycle, from
sporozoite to oocyst, in only a select few chicken embryos and cultured cell systems (30,
31). Chorioallantoic endodermal cells (30), primary chicken kidney cells, human fetal
lung cells, pig kidney cells (31), human endometrial cells (95), and human colon
carcinoma cells (34), have been proposed as in vitro cultures for evaluation of
anti protozoan drugs. However, these systems limit the extent of multiplication, provide
few infective oocysts, and are difficult to perform. This marked preference of C. parvum
to some culture systems as opposed to others is not yet understood and deserves further
exploration.
In Vivo Experimentation. Experimental research involving numerous animal
species has been employed in the study of C. parvum infection in hopes of characterizing
a reliable model. To date, the most widely used and inexpensive animal models have
been rodents. Wild as well as laboratory rodents have been experimentally infected with
C. parvum (28, 41, 44, 52, 55, 65, 111, 116, 120) and examined for their use in
characterizing the pathogenesis and immune mechanisms associated with
cryptosporidiosis. Attempts to develop a reliable immunocompetent adult rodent model
have been unsuccessful (52, 119).

I3
In selecting animal models, considerable attention has been devoted to their immune

status and subsequent susceptibility to C. parvum. As in human infections, persistent
animal infections require that the host be immunocompromised. This fact has led to the
examination of experimental infections in animals with immature immune systems
(neonates) and animals that are immunocompromised as a result of either genetic
immunodeficiency or administration of exogneous immunosuppressive drugs.
Neonatal animal models available to study cryptosporidiosis include suckling mice,
calves, piglets, and lambs (28, 41, 119, 121).

Experimental studies conducted in

neonates indicate that, although they are initially susceptible to C. parvum infections, the
rapid maturation of their immune systems and development of innate immunity quickly
eliminates C. parvum. Initial studies showed that while neonatal (1-4 days old) mice
could be asymptomatically infected, mice 21 days or older exhibited a transient infection
(111). Other research involving neonatal mice demonstrated development of patent
infections in approximately 4 days, oocyst shedding for up to 9 days, followed by
spontaneous clearing of the infections within 3 weeks (28, 41, 55). However, when the
host was immunosuppressed, the disease became chronic, with the host exhibiting severe
signs of infection closely paralleling those seen in human infections. Hence, the use of
conventional neonatal animal models is limited due to the short-term nature of the disease.
This short duration of infection limits the period necessary to effectively screen
prophylactic or therapeutic agents. In addition, drug administration to neonates usually
requires labor-intensive procedures because neonates are neither metabolically nor
biologically well developed. Thus, the neonatal model fails to lend itself as a reliable
model for effective evaluation of anti-C. parvum drugs.
Attempts to infect immunodeficient adult animals have also received some attention.
Ungar et a!. (122) has described adult athymic and T-ee!! subset-depleted mice as
possible models of chronic symptomatic cryptosporidiosis. More recently, severe
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combined immune deficient (SCID) and Nlli-ill (bg/nu/xid) mice have been examined as
possible animal models for C. parvum infections (75). These and similar studies have
shown that genetically immunodeficient mice are susceptible to C. parvum infections as
neonates and as adults (75). In addition, these models have utility for screening potential
anti-cryptosporidial agents. However, their inbred genetic disorder does not allow one to
determine the immunological status of the animal. Furthermore, immunomodulating
agents can not be screened using a genetically immunodeficient model. This proves to be
a disadvantage based on the general agreement that immunological as opposed to
physiological responses of the host result in termination of the parasite's life cycle and
full recovery from infection (29, 60).
Other laboratory animal models previously tested for cryptosporidiosis include
guinea pigs, hamsters, primates, and a number of wild and domestic species (4, 19, 39,
79, 104). However, demands on expense, availability, and handling of these animals, as
well as their resistance to glucocorticoid-induced immunosuppression (20), have limited
their use. Controversy regarding the etiological agent of disease (a species other than C.
parvum) has also caused some concerns (4, 19, 124, 125). Whether or not the .disease in

these animals is due to C. parvum or another species is still not clear, and thus merits
further investigation.
Based on findings which suggest that patent and pre-patent periods of C. parvum
differ between immunocompetent and immunocompromised hosts, anticryptosporidial
drugs intended for use in immunocompromised hosts should be evaluated in an
immunocompromised model (98).

Also, as stated by Brasseur et al. (15:1037), "the

validity of a rodent model as a model for human cryptosporidiosis is supported by 1) the
identification of the parasite in the different hosts, and 2) the similarity of infections in
both immunosuppressed humans and rodents."
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Immunocompromising Agents. In order for chronic C. parvum infection to
persist, the host needs to maintain a state of immunosuppression. This is supported by
research involving cryptosporidial infections in malnourished children, genetically
immune deficient rodents, humans receiving immunosuppressive therapy, and AIDS
patients (39). All of these hosts exhibit chronic and often fatal cases of the disease.
Therefore, in order to mimic the signs and symptoms associated with chronic
cryptosporidiosis, as would be seen in immunosuppressed or immunodeficient patients,
the animal model must be immunosuppressed.
Some of the more common immunosuppressants that have been used in animals
and humans include cyclosporin, hydrocortisone acetate, cyclophosphamide, and
dexamethasone (15, 57, 73, 77, 80, 92, 94, 97, 98, 107). All of these agents have and
are still being utilized in research as well as clinical work. Rodent models relying on the
administration of the aforementioned immunosuppressants as a means of facilitating
susceptibility to C. parvum infection have been described (15, 97, 98, 104).
Cyclosporin, a commonly used immunosuppressive agent in cancer chemotherapy
and organ transplants has, for the most part, proven quite successful in this regard. Its
mechanism of immunosuppression involves the inhibition of lymphokine secretion (63),
and interference with enzymes essential for the tertiary folding of proteins (51).
However, complications associated with the use of cyclosporin, including renal
dysfunction, hypertension, tremors, and convulsions, have limited its use. In addition,
excessive doses have proven to be highly hepatotoxic and nephrotoxic, with the later
occurring in 25-75% of patients on cyclosporin therapy (107).
Hydrocortisone acetate has been used in conjunction with a low protein diet in
rodents to induce susceptibility to C. parvum (15). However, this immunosuppressive
regimen has not been attractive because it is expensive and may result in decreased
antibody production with an apparent increase in cell-mediated immunity (CMI).
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Because research has suggested an important role of both the humoral and CMI
responses of the host in clearing cryptosporidiosis, this regimen has been avoided in
most research protocols.
Cyclophosphamide is among the more common immunosuppressive agents
associated with establishing susceptibility to cryptosporidiosis in humans (57, 73, 77,
80) and animals (5, 97). Studies demonstrated that cyclophosphamide therapy induced
delayed toxicity in rodents (5, 97). In addition, cyclophosphamide administration was
required in higher doses and for longer periods to provide sufficient immunosuppression
in rats to allow for C. parvum colonization (97). Consequently, the anticryptosporidial
activity of potential therapeutics could not be tested as soon with a cyclophosphamideimmunosuppressed animal model. Furthermore, cyclophosphamide has also been
reported as being an anti-proliferative agent against a myriad of dividing cells, and
therefore is not specific for cells of the immune system.
Dexamethasone (DEX) is a synthetic glucocorticoid (GC) known to have potent
anti-inflammatory and immunosuppressive activity (20, 21, 27, 51, 70, 90) . Natural
glucocorticoids are hormones secreted from the adrenal cortex in response to various
stimuli, and have been shown to have striking pharmacologic effects on tissues and cells
of lymphoid origin (20). Natural steroid therapy generally requires large doses and at
times localized administration, which has often limited the use of these compounds (81).
The overall potency and effectiveness of synthetic steroid analogs can readily be
controlled by slight conformational and structural alterations (70).
Dexamethasone is known to suppress the immune system by non-selective and
selective mechanism(s). The mechanisms, though obscure, are considered non-selective
for the following reasons: species differences in susceptibility to glucocorticoids,
heterogeneity of lymphoid cells within the same species, and presence of specific
intracellular glucocorticoid receptors (II) and biochemical events responsible for
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subcellular effects (20). Nonetheless, the majority of DEX-mediated mechanisms are
selective. The mechanism of action of this steroid involves controlling the rate of protein
synthesis at the cellular level (22, 51). The most widely accepted mechanism suggests
that DEX accomplishes this by reacting with specific protein receptors located in the
cytoplasm of sensitive cells, resulting in the formation of a steroid-receptor complex (22,
51). Recent studies have demonstrated, however, that the initial binding of hormone and
receptor may actually occur inside the nucleus. The hormone-receptor complex, after
undergoing structural modification involving the dissociation of a 90 Kd protein from the
receptor, migrates to the chromatin of the cell where it binds to DNA and regulates gene
transcription. In most cases, transcription is enhanced, resulting in an increase of
mRNA. However, some known examples have shown evidence of a decrease in gene
transcription (51).
Animals have been divided into GC-sensitive and GC-resistant species based on the
ease of producing lymphoid depletion following a regimen of systemic GC administration
(20). Glucocorticoid-resistant species include most domestic animals as well as man,
ferret, guinea pig, and monkey, whereas the rat, mouse, hamster, and rabbit are
considered GC-sensitive. Most of the information concerning the effects of GC on
immunologic processes and lymphoid cells have been derived from experiments
involving GC-sensitive species. Therefore, extrapolation of these experimental results to
GC-resistant species should be done with discretion. Opposing effects of DEX on
lymphocyte populations in GC-resistant versus GC-sensitive species have been
documented (22).
The biologic half-life of DEX varies depending upon the route of administration and
the species receiving the immunosuppressive therapy. In humans, where DEX has been
administered intravenously or orally, the half-life has been reported to range from 36 to
72 hours (14, 51), with blood lymphcyte counts reaching minimum values between 4-8
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hours postdosing (14). In other studies, the half-life has ranged from 2 to 9 hours in
humans (20). Unfortunately, there is very little information regarding kinetic modeling
of DEX in rodents.
Data suggest that GC administration has suppressive effects on both humoral and
cell-mediated immunity (94), with the latter requiring prolonged treatment or large doses
before measurable effects are apparent (20). Humoral immune responses are indirectly
influenced by GC and are believed to be differentially affected by GC
immunosuppression depending on species sensitivity. In GC-sensitive species, DEX
results in decreased production of circulating antibodies and inhibits lymphocyte response
to mitogen stimulation (12, 22, 48, 72, 94). In GC-resistant species, DEX treatment
produces enhanced responses of B and T lymphocytes to mitogens (22). Some of the
immunosuppressive effects of DEX on lymphoid cells include in vivo thymic involution
(20), in vitro thymocyte destruction (71), inhibition of cellular activation and metabolism
(20), redistribution of lymphocytes (20), and profound effects on peripheral lymphoid
tissues such as spleen and lymph node shrinkage (20).
Dexamethasone-immunosuppressed rodent models for studying cryptosporidiosis
have been partially characterized (92, 94, 98). The dose and route ofDEX administration
appear to be critical when attempting to induce an infection (98). Genetic differences
between rodent species also play a role in the effects DEX has on the immune system
(92). In any event, the consistent, low-toxic immunosuppression produced by DEX, and
the subsequent susceptibility of the host to C. parvum, supports the use of this drug in
the development of a rodent model for studying chronic cryptosporidiosis.

Adrenal Steroids as Chemotherapeutics. The adrenal cortex synthesizes
two classes of steroids, namely corticosteroids (mineralocorticoids and glucocorticoids)
and

androgens,

which

includes

dehydroepiandrosterone

(DHEA).

Dehydroepiandrosterone, 3-beta-hydroxyandrost-5-en-17-one is one of the most
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abundantly secreted adrenal cortical steroids in humans and other mammals (67, 88,
126). The level of DHEA increases during early adolescence and decreases to nearly 5%
of its original level with old age (67 , 88). There are substantially lower levels of DHEA
in people exhibiting signs of chronic illness and stress (110), Alzheimer's disease (113) ,
those with type A personalities (43) and HIV-infected patients (78). The physiological
significance of the progressive decline in DHEA is not yet fully understood.
A number of in vitro and in vivo experimental fmdings provide evidence that DHEA
administration to research animals has beneficial effects on a number of physiological and
metabolic parameters. Some of these effects include treatment of diabetes in genetically
obese (23) and diabetic mice (24 ), increased tissue sensitivity to insulin in aged normal
mice (25), and decreased weight gain in young animals without altering food intake
(127). In rodents, DHEA has been shown to increase lifespan (68), inhibit spontaneous
breast cancer (109), increase resistance to carcinogen-induced cellular transformations
(45, 86), restrain autoimmune diseases (68 , 114), and up-regulate the immune system
(13, 67, 103).

Administration of DHEA has been shown to be associated with

enlargement of splenic germinal centers, suggesting a direct stimulation of the B
lymphocyte dependent areas (67). In contrast, as reported by Risdon eta!. (101), normal
mice given dietary DHEA showed an appreciable decrease (50%-60%) in lymphoid organ
cellularity, suggesting that the route ofDHEA administration may be an important factor
influencing its potentiating effects on the immune system.
The molecular basis for the potentiating effect of DHEA on the immune system is
not clear. As the concentration of DHEA declines, so does the competency of the
immune system (13, 71, 103, 115). In humans and to a lesser degree in rodents, DHEA
is converted by an adrenal sulfokinase to its sulfate ester metabolite,
dehydroepiandrosterone sulphate (DHEAS). Observations based on the research of Loria
et al. (67) suggest that protection with DHEA occurs through a pathway other than
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sulfation. Their findings are supported by Browne eta!. (16) who suggested that the
prohormone DHEAS is biologically inactive and much less potent than DHEA. In
contrast, Daynes et a! . (36) administered DHEAS to aging mice and completely restored
immune function. Risdon et a!. (102) have shown that lymphopoiesis (lymphocyte
production from bone marrow and thymus) is inhibited by DHEA, while having no effect
on myelopoiesis (red blood cell production from the spleen). The DHEA may possess its
own thymus cell-receptor, thus allowing it to exert effects directly on the thymus (71 ).
However, May eta!. (71) questioned the independent DHEA thymus receptor, observing
that the protective effects of DHEA were present only when administered in vivo. This
suggests that the effect may possibly be mediated at a site located elsewhere in the body,
or the effect may be due to a necessary androgenic metabolite of DHEA. Experiments
utilizing androstenedione, the most active metabolite of DHEA, failed to show any
immune protective effect, ruling out the likelihood that androgens are involved in the
mediating pathway (13, 71, 103). Experiments showing evidence of a direct effect of
DHEA on central nervous tissues (46) support the possibility of a distant receptor site for
this antiglucocorticoid.

A DHEA-specific receptor has been found on murine T

lymphocytes (76). Whether or not this receptor is present on lymphocytes of other
animal species is speculative. Risdon eta!. (102) concluded that DHEA acts selectively
by suppressing lymphocyte progenitors as opposed to mature lymphocytes and that
growth and maturation of B, T, and natural killer cells occurred by mechanisms other
than interleukin 2 (IL-2) inhibition. Daynes eta!. (35, 37, 38) have demonstrated that
DHEA enhances IL-2 production by activated helper T lymphocytes. In vitro and in vivo
administration of DHEA overcomes GC-induced depressions in IL-2 and gamma
interferon (IFN) production (38). Studies in mice have demonstrated that protective
immunity to opportunistic infections like cryptosporidiosis, requires he! per T
lymphocytes expressing IL-2 and gamma-IFN production (55, 75, 122). Individuals
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infected with HIV exhibit elevated blood levels of GC (55) , yet display depressed levels
of DHEA (cb). This shift in steroid hormones in AIDS patients could possibly facilitate
their increased susceptibility to infectious agents such as C. parvum. Furthermore, agerelated changes in host defense mechanisms have been reversed by the administration of
DHEA (36, 93).
Dehydroepiandrosterone has been used clinically in both topical and systemic
regimens to treat such conditions as gout, psoriasis, hyperlipemia, and postcoronary
illnesses. In animals and humans, DHEA has shown promise as an anti-obesity (84,
127) and anti-carcinogenic agent (56, 66, 105, 108). Some of the more prevalent
findings involve the potentiating effects DHEA has on the immune system (13, 67, 103).
Side effects of DHEA have been minimal as reported by Loria et al . (67) and others (84,
96). Despite the efficacy of DHEA in treating such a myriad of disorders, there is no
undisputed mechanism(s) of chemoprevention.

Potential mechanisms have been

proposed by Risdon et al. (101), including induction of peroxisomal proliferation and/or
modification resulting in alterations of liver metabolism, caloric restriction, conversion of
oral DHEA to active metabolites such as estrogens and androgens, and inhibition of
glucose-6-phosphate dehydrogenase.
The implications of using this native steroid to treat a variety of disorders are
numerous, and through continued experimental research, the biological mechanism(s) of
DHEA will be elucidated. Because clinical studies using DHEA have shown evidence of
minimal side effects, the utility of this immunomodulator as a possible prophylactic
and/or therapeutic agent against opportunistic infections like cryptosporidiosis merits
intensive study.
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MATERIALS and METHODS
Animals.

Five- to six-week-old, female C57BL/6N mice (Simonsen

Laboratories, Gilroy, CA), weighing 14 to 16 g, were used in this study. Rasmussen et
a!. (92) showed that the DEX-immunosuppressed C57BL/6N mouse could be
successfully infected with C. parvwn, resulting in a chronic infection. Female mice were
used to decrease variability associated with steroid regimens and because their behavior in
caged groups is less aggressive.
All mice were maintained in the American Association for the Accreditation of
Laboratory Animal Care (AAALAC)-accredited Laboratory Animal Research Center at
Utah State University. The animals were housed five per cage (unless otherwise
indicated) in plastic shoe-box cages on com-cob bedding and received commercial lab
chow (Wayne Lab Blox, Allied Mills, Chicago, IL) and water ad libitum. Animal cages,
bedding, and drinking water were changed once per week. Room conditions were
maintained with a 12 hour light-dark cycle at 20-22°C with 40-60% relative humidity and
14-18 air changes per hour using 100% fresh air exchange. The room static pressure
remained negative relative to the adjoining hallway. The animal cages were housed in a
ventilated animal rack (Lab Products). Exhaust air from the rack was HEPA-filtered and
recirculated back into the room. All live animal handling was done in a Bio-hazard hood.
To prevent accidental infection between animals and personnel, BSL-2 safety standards
were maintained (91).

Immunosuppression or Mice. The synthetic glucocorticoid, dexamethasone
(DEX; Sigma Chemical Co., St. Louis, MO) was used to immunosuppress the mice.
The mice were immunosuppressed for 12 days (unless otherwise specified) prior to C.

parvum oocyst inoculation, and were continued on DEX throughout the remainder of the
experiments. The immunosuppressive regimen consisted of daily intraperitoneal (i.p.)
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injections of DEX at a concentration of 125

~g/mouse/day

unless otherwise indicated. In

shon, DEX was dissolved in 100% ethyl alcohol and stored as a stock solution at 4°C.
Just prior to i.p. injection, DEX was diluted in sterile deionized water to the desired
concentration and a total volume of 200 ~ per mouse was injected using a sterile 27 -gage
needle. To reduce physical trauma caused by daily i.p. injections, needles were replaced
often (e.g., a maximum of five injections per needle). A group of mice were also
immunosuppressed with DEX administered orally in the drinking water. A stock
solution of DEX at a concentration of 8 ~g/ml was prepared weekly as described. The
DEX was added to individual water bottles for each cage and the mice had free access to
the water.

Parasites. The C. parvum oocysts used to infect the mice were obtained
originally from Harley Moon (U.S. Department of Agriculture, Ames, IA) (8). This
Iowa isolate was used to orally infect newborn Holstein calves, which provided a source
of fresh oocysts. The oocysts were purified from the calf feces using discontinuous
sucrose gradients as described by Arrowood et al. (6), and stored in 2.5% potassium
dichromate at 4°C for a maximum of four months before being used to infect the mice.
Prior to orogastric administration, the oocysts were washed to remove the
potassium dichromate. Briefly, a calculated volume of oocyst suspension was placed
into a polypropylene centrifuge tube (Coming Glass Works, Coming, NY) that had been
precoated with RPMI-1640 (GffiCO BRL, Grand Island, NY) supplemented with 10%
fetal bovine serum (FBS; Hyclone Laboratories, Logan, UT). This protein coating
prevented the oocysts from adhering to the wall of the centrifuge tube. An equal volume
of RPMI-1640 base medium was added to the oocyst suspension and mixed gently. The
oocyst-RPM! suspension was centrifuged for 10 min. at 2000 x g, the supernatant
di scarded, and the pellet resuspended in 20 ml of RPMI-1640 base medium. The
suspension was centrifuged, the supernatant discarded, and the pellet resuspended two
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more times as described. The final total volume of resuspension was in 2-5 ml of RPMI1640 base medium. Immediately before administration, the oocysts were counted using a
hemocytometer. Each mouse was intragastrically inoculated with approximately J06
clean oocysts in a volume of 200 Jll of RPMI-1640 base medium. The oocysts were
administered using a 22-gage straight feeding needle (Thomas Scientific, Swedesboro,
NJ). The inoculum was repeatedly mixed to insure each mouse received equal numbers
of oocysts.

Fecal Collection and Examination. Infection intensity was determined by the
number of C. parvwn oocysts excreted in the feces. To monitor the oocyst shedding in
infected mice, fecal pellets were collected from each mouse per rectum throughout the
experiment. The fecal pellets were suspended in a volume of 2.5% potassium dichromate
approximately equal to that of the feces and stored at 4°C for a minimum of 24 hrs. Fecal
material was mixed and smeared onto glass microscope slides and observed for the
presence of C. parvwn oocysts using an oocyst-specific monoclonal antibody-based
indirect immunofluorescence assay (7). Generally, 40 microscopic fields (400x) were
examined for the presence of oocysts. Fecal smears were examined in a blind fashion
and different treatment groups were compared according to mean oocyst numbers per
fecal smear. Raw fecal counts for each treatment group were subjected to statistical
analysis.

Histological Collection and Examination. Periodically, mice from each
treatment group were euthanized and necropsied, and tissues were collected and
examined for parasite colonization. Prior dates were established for sacrificing mice.
However, at times it was necessary to sacrifice mice displaying abrupt clinical
deterioration (loss of skin tone, lethargy, emaciation). Mice were euthanized by
overexposure to carbon dioxide. Following sacrifice, a complete gross examination of all
organs was performed and any abnormalities were noted. Spleens were collected
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aseptically and weighed as a representation of the immune status of the animal . The
spleens intended for use in immunological assays were temporarily stored in RPMI-1640
base medium supplemented with 10% FBS while other spleens were fixed in 10% neutral
buffered formalin for histological analysis.
Tissue samples harvested from the heart, lungs, liver, gall bladder, kidney, uterus,
urinary bladder, stomach, pancreas, duodenum, jejunum, ileum, cecum, and colon were
fixed in 10% neutral buffered formalin. Tissues were stored at least one week in
formalin prior to sectioning. Histological sections were embedded in paraffin, sectioned,
and stained with hematoxylin and eosin (H & E). Stained tissues were examined using
brightfield microscopy in a blind fashion to determine parasite colonization and presence
of histopathologic lesions. Generally, intestinal tissue was scored numerically by viewing
10 random fields (400x.) examining a total of 0.5 em of intestinal tissue with raw parasite
numbers recorded. Nonintestinal tissues were examined and scored on a percentage
basis as follows:
parasitized; 2+

0

= parasites

not observed; 1+

=<

= 10-50% of epithelial surface parasitized;

10% of epithelial surface
3+

= 50-90% of epithelial

surface parasitized; and 4+ = >90% of epithelial surface parasitized. For each treatment
group, the average number of cryptosporidia at the epithelial surface of infected tissues
was determined and parasite counts were subjected to statistical analysis (9).

Immunologic Paramaters. The immunologic parameters examined were the
functionality of splenic B and T lymphocytes in response to the mitogens
lipopolysaccharide (LPS) and concanavalin A (Con A). The mitogens served as agents
(antigens) to stimulate mitosis in mouse B and T lymphocytes.

Splenocyte preparation. Spleens were collected aseptically, weighed,
and temporarily maintained in 15 ml polypropylene centrifuge tuhes (Corning) containing

5 ml of RPMI-1640 base medium (GIBCO). The base medium consisted of 99% RPMI1640 (GIBCO) and 1% penicillin-streptomycin (1000 U penicillin-G/ml plus 1000 J.lg
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streptomycin/ml) (GIBCO). The penicillin-streptomycin served to inhibit bacterial
growth from possible contamination. Individual spleens and media were poured into
plastic seward medical stomacher bags (Tekmar Company, Cincinnati, OH). Three bags
were simultaneously homogenized using a stomacher (Tekmar) to create single cell
suspensions. Spleen cell suspensions were poured back into their original 15 ml tubes,
centrifuged at 200 x g for 10 minutes, and the supernatant discarded. Red blood cells
were removed by hemolysis using 9 ml of sterile, deionized water. The remaining
lymphoid cells were quickly (within 5 seconds after adding water) brought back to
physiological pH by adding I ml of I 0 X phosphate buffered saline (PBS) adjusted to a
pH of 7.2-7 .6. Any connective tissue debris was removed using sterile wooden
applicator sticks. Remaining splenocytes were centrifuged a second time (10 min. at 200
x g), the supernatant discarded, and the pellet resuspended in 10 ml of RPMI-1640 base
medium. Cell suspensions were centrifuged a third time (10 min. at 200 x g), the
supernatant discarded, and the pellet resuspended in 5-10 ml of RPMI-1640 complete
medium containing 20% FBS (Hyclone). The complete medi um consisted of RPMI1640 with I% penicillin-streptomycin, I% 5 mM 2-mercaptoethanol (2-ME; Sigma), and
I% sodium pyruvate (GIBCO). The FBS provides necessary growth factors for cell
division. The 2-ME stimulates murine macrophages which, in tum, are necessary forT
lymphocyte stimulation.

And, the sodium pyruvate provides essential energy

requirements of the cells. The individual cell suspensions were then counted using a
Coulter Counter (Coulter Electronics, Hialeah, FL) and adjusted to 5 x J05 cells/mi.
Splenocytes were used in B and T lymphocyte mitogen-induced proliferation assays to
determine the immune paramaters affected by DEX immunosuppression and C. parvum
infection .
B and T Lymphocyte Proliferation Assays. The

blastogenic

response of spleen cells to the B lymphocyte mitogen Escherichia coli lipopolysaccharide
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( 10, 5 and 2.5 !lg/ml; Sigma) and the T lymphocyte mitogen concanavalin A (5, 2.5 and
1.25 !lg/ml; Sigma) were determined to assess general B and T lymphocyte function.
The mitogen doses chosen were based on previous findings representing maximal
response in our cell culture system (unpublished data). A total of 5 x !OS spleen cells in
0.1 ml volumes of RPMI, 10% FBS, and 2-ME was added to triplicate wells of 96-well
flat-bottom microplates (Coming). A volume of 0.1 ml of each mitogen dilution in a
sol ution containing 10% FBS in RPMI-1640 was added to each well in triplicate.
Controls consisted of wells containing only RPMI-1640 base medium and 0.1 ml spleen
cells (5 x 105). The plates were incubated for 72 hrs at 37°C in a humidified atmosphere
of 5% C02.
[ 3 H]thymidine

Synthesis of DNA was measured by the addition of 0.5 !lCi/well
(4 !lCi/ml; New England Nuclear Corp., Boston, MA) for 4 hrs.

Thymidine incorporation was determined by harvesting cells on glass fiber filter paper,
followed by counting on a Packard 1500 scintillation counter. Lymphocyte proliferative
response was determined using counts per minute (CPM) and represented as mean CPM.
Mean CPM were calculated by dividing the average of the sample CPM by the average of
the control CPM for that same mouse.
Statistical Analysis.

For each day that fecal specimens were collected, the

number of C. parvum oocysts per mouse per 40 microscopic fields (400x) was averaged
for each experimental group to obtain a group mean. Tissue colonization by the parasite
was determined for each infected mouse by counting total parasite numbers associated
with 0.5 em of tissue (intestinal sections) or percent colonized (nonintestinal sections)
and group means were calculated. Group means± standard error (SE) were reported for
each experimental group. One-way and two-way analyses of variance (ANOVA) were
performed to compare differences within and between groups when appropriate. For
A NOVA, Fisher Protected LSD or Scheffe tests (Macintosh version) were used to do
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mean comparisons when differences existed among treatment groups. A significance
level of 95 % was set for each test to denote significant differences between groups.
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EXPERIMENTAL DESIGN
Characterization of Chronic Cryptosporidiosis in Immunosuppressed
Mice. This study was designed to examine the chronicity of C. parvum infections in
DEX-immunosuppressed C57BU6N mice. Two experiments were performed, the first
of which was a "pilot" study used to define the parameters associated with a chronic
infection in this mouse model. The second experiment was a "follow-up" to the pilot
study in which modifications to optimize the model were incorporated.
In the pilot study, four groups of mice were studied (Table 1). Group-! (Normal)
consisted of eight mice housed four per cage, none of which were immunosuppressed or
challenged with the parasite. Group-2 (Cp only) consisted of 12 mice housed five per
cage with the exception of one cage which contained only two mice. All mice in group-2
were chailengeri with the parasite but were never immunosuppressed. Group-3 (DEX
only) consisted of 20 mice housed five per cage, none of which were challenged with
parasite, but all were immunosuppressed. Group-4 (DEX + Cp) consisted of 22 mice
housed five per cage with the exception of one cage containing two mice. All mice in
group-4 were immunosuppressed and challenged with the parasite.
The DEX was administered i.p. daily (125 J.Lg/mouse/day) for 12 days prior to C.
parvum oocyst inoculation and continued throughout the duration of the experiment.

Each mouse receiving the parasite was intragastrically inoculated with 0.2 ml of a
suspension containing 106 oocysts. Fecal samples were collected per rectum each day
from individual mice for the first 2 weeks and weekly thereafter, until the end of the
experiment. Oocyst shedding was monitored by immunoflourescent assay of the fecal
pellets (9, 47). Individual mouse weights were recorded weekly and the overall
appearance and health status of the mice was noted throughout the experiment. The study
was carried out for 4 months in order to examine the chronic phase of the disease.
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Mice from each treatment group were necropsied bimonthly or when moribund ,
beginning on day one following inoculation with the oocysts. Due to monality, the
number of mice sacrificed in each treatment group varied. Mice were euthanized by
overexposure to carbon dioxide.

Following euthanasia, spleens were collected

aseptically and weighed as a general representation of the immune statue of the mice. The
entire gastrointestinal tract of necropsied mice was dissected and sections of the hean,
lungs, liver, gall bladder, kidney, uterus, stomach, pancreas, duodenum, jejunum,
ileum, cecum, colon, and urinary bladder were fixed in 10% formalin. Histological
sections were stained with hematoxylin and eosin (H & E) and examined using
brightfield microscopy to determine parasite colonization. The average number of
cryptosporidia at infected epithelial surfaces was determined and parasite counts were
subjected to statistical analysis (9).

Table I. Experimental design for the pilot study of chronic Cryptosporidium parvum
infections in mice.
Group
I (Normal)
2 (Cponly)
3 (DEXonly)
4 (DEX+Cp)

n

DEX

C.parvum

(I 25 flYmousc/day)

(I o6 oocysiS/mouse)

8
12
20
22

+
+
+

+

Cp ; C. parvum; DEX ; dexamethasone

The chronic experiment was repeated with the following modifications and is
recognized as a "follow-up" study.

Five groups of mice were studied (Table 2).

Group-! (Normal) consisted of 10 mice housed five per cage and received neither DEXimmunosuppression nor were challenged with parasites. Group- ! mice were given i.p.
injections of a 10% alcohol solution as a placebo on the same sched ule as those mice
receiving DEX i.p. Group-2 (Cp only) consisted of 20 mice housed five per cage, each
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receiving the parasite without being immunosuppressed. Group-2 mice also received i.p.
injections of a 10% alcohol placebo in accordance with the i.p. DEX schedule. Group-3
(DEX only) consisted of 50 mice housed five per cage. Each mouse in group-3 received
DEX-immunosuppression but was never challenged with the parasite. Group-4 (DEX +
Cp) consisted of 50 mice housed five per cage. Each mouse in group-4 received DEXimmunosuppression and parasite challenge. Group-5 (DEX + Cp) consisted of 47 mice
housed five per cage with the exception of two cages which contained six mice. Each
mouse in group-5 received parasite challenge; however, DEX was administered in the
drinking water (8 j.lg/ml) ad libitum rather than being administered i.p.
In groups 1-4, DEX (125 j.lg/mouse/day) was administered i.p. daily for 12 days
prior to C. parvum oocyst inoculation (106 oocysts) and continued until the 8th week
post-infection. At this time, the DEX regimen was administered only 6 days per week
ana continued throughout the duration of the experiment.

Parasite inoculation, fecal

examination, euthanasia, and histological collection and examination followed the same
protocol as described previously. The study was carried out for 4 months in order to
examine the chronic phase of the disease.

Table 2. Experimental design for the follow-up study of chronic Cryptosporidium
parvum infections in mice.
Group
I (Normal)
2 (Cp only)
3 (DEXonly)
4(DEX +Cp)
5 (DEX + Cp)•

n

10
20
50
50
47

lntrapentoneal
Injection
JO% alcohol
10% alcohol
DEX
DEX
None

C. parvum
(I o6 oocysts/mouse)

• mice in group-S were immunosuppressed orally with DEX (8
DEX =dexamethasone (125 ~g/mouse/day); Cp =C. parvum

+
+
+
~g/ml).
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Effects of Cryptosporidium parvum and Dexamethasone on 8 and T
Lymphocyte

Proliferation.

These studies were designed to determine if

susceptibility to C. parvum infections in immunosuppressed mice correlated with
decreased in vitro B and T lymphocyte responses to the mitogens LPS and ConA,
respectively. Furthermore, these studies were designed to determine if C. parvum
effected immunosuppression on the hosts.
Thirty-two mice were randomly assigned to four groups as shown in Table 3.
Group- I consisted of six mice receiving neither DEX nor parasite challenge (Normal);
group-2 consisted of six mice receiving no DEX but were challenged with the parasite
(Cp only); group-3 consisted of 10 mice receiving DEX without parasite challenge (DEX
only); and group-4 consisted of 10 mice receiving DEX and parasite challenge (DEX +
Cp). All mice were immunosuppressed daily for 14 days with i.p. injections of DEX
(125 J..Lg/mouse/day) after which each mouse (those assigned to receive parasite
challenge) was intragastrically inoculated with 1()6 C. parvum oocyst. All mice on
immunosuppression continued to receive DEX i.p. throughout the duration of the
experiment. Mice and facilities were maintained as described.

Table 3. Experimental design for examining the effects of Cryptosporidium parvum and
dexamethasone on B and T lymphocyte proliferation in mice.
Group

n

I (Normal)
2 (Cp only)
3 (DEX only)
4(DEX + Cp)

6
6
10
10

Mice sacrificed I
week p.i.
3
3
5
5

Mice sacrificed 2
weeks p.i.

3
3
5
5

Cp = C. parvum; DEX =dexamethasone; p.i. = postinfection

At I week postinfection (p.i.), 16 mice (half from each group) were sacrificed and
at 2 weeks p.i. the remaining 16 mice were sacrificed. At the time of sacrifice, spleens
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were collected and prepared for use in a B and T lymphocyte proliferation assay as
described in the Materials and Methods. The assay was used to determine the effects
DEX and/or C. parvum had on lymphocyte functionality.
Effects of Dehydroepiandrosterone on Oocyst Shedding Intensities of
Mice Infected with Cryptosporidium parvum. This experiment was designed to
determine if the immunomodulator dehydroepiandrosterone (DHEA) and its sulfated
conjugate, DHEA-sulphate (DHEAS), increased resistance to C. parvum in
immunosuppressed mice.
All mice in this experiment were immunosuppressed intraperitoneally (i.p.) with
DEX (125 Jlg/mouse/day) for 12 days and then challenged with 106 C. parvum oocysts
as described previously. The mice continued to receive DEX i.p. throughout the duration
of the experiment Thearpeutic treatment with DHEA or DHEAS began 35 days p.i. and
continued daily through day 63 p.i., resulting in 28 days of treatment for a chronic
infection.
Thirty-seven mice were randomly assigned to four groups as shown in Table 4.
Group-! consisted of four mice and served as a control group receiving DEX and parasite
challenge, but no DHEA or DHEAS. Group-2 consisted of 12 mice equally divided into
three subgroups receiving DEX, parasite challenge, and DHEA per os (p.o.) at a dose of
50, 150, and 300 Jlg/mouse/day. The DHEA was administered in a total volume of 100
J.!l of a peanut-oil vehicle. Group-3 consisted of 12 mice equally divided into three
subgroups receiving DEX, parasite challenge, and DHEA subcutaneously (s.c.) at a dose
of 3, 6, and 12 mg/mouse/day dissolved in 250 J.!l of a 100% propylene glycol solution
(36). Group-4 consisted of 9 mice equally divided into three subgroups receiving DEX,
parasite challenge and DHEAS s.c. at a dose of 3, 6, and 12 mg/mouse/day dissolved in
250 Jll of sterile, deionized water (36). The different DHEA and DHEAS solutions were
prepared fresh every week and stored at 40C as stock solutions. Each DHEA or DHEAS
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suspension was warmed to room temperature before daily administration . Mice and
facilities were maintained as described in the Materials and Methods.
Fecals were collected per rectum daily, and examined for C. parvum oocysts. The
oocyst shedding patterns for the individual groups were used to determine infection
intensity. The overall health status and activity of the mice were noted throughout the
study. Mice were sacrificed when moribound up until day 28 posttreatment with DHEA
or DHEAS, at which time all remaining animals were sacrificed. At the time of sacrifice,
any gross abnormalities were noted and spleens were collected and weighed as a general
representation of the immune status of the mice.

Table 4. Experimental design for examining the effects of dehydroepiandrosterone
(DHEA) and dehydroephndrosterone-sulfate (DHEAS) on the oocyst shedding
intensities of mice infected with Cryptosporidium parvum.
Group
I
2a
2b
2c
3a
3b

3c
4a•
4b 0

4c.

n
4
4
4
4
4
4
4
3
3

3

DHEA(S) dosage
none
50 Jlg
ISO Jlg
300 Jlg
3mg
6mg
12mg
3mg
6mg
12mg

DHEA(S) route
none
p.o.
p.o.
p .o.
S.C.
S. C.
S.C.
S.C .
S.C.
S.C.

• mice in group-4 received DHEA-sulfatc (DHEAS)
p.o. = per os; s.c. = subcutaneous

Vehicle
none
peanut oil
peanut oil
peanut oil
propylene glycol
propylene glycol
propylene glycol
sterile water
sterile water
sterile water
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RESULTS
Characterization of Chronic Cryptosporidiosis in Immunosuppressed
Mice. This pilot study was designed to examine the chronic nature of cryptosporidiosis
in the DEX-immunosuppressed mouse model (92). Initially, a predetermined number of
mice from each treatment group (random selection) were assigned to be sacrificed on a
bimonthly schedule. As the immunosuppression continued and the infection intensified,
many of the mice began to show clinical signs of deterioration that resulted in a number
of unexpected deaths. As a result of this unanticipated loss of mice and in an attempt to
maintain sufficient animal numbers to last the 4-month duration, the DEXimmunosuppression was reduced. In short, between weeks 8 and 10 of the experiment
DEX administration was reduced from daily dosing to dosing every other day. This
de.::r.:ase in inmmnosupptessiou resuited in a rapid decline in oocyst shedding between
weeks 8 and 12 postinfection (Figure 2). As the condition of the mice improved, DEX
dosing was again administered daily, which explains the rapid increase in oocyst
shedding toward the end of the experiment
The prepatent period for mice infected with C. parvum was 3 days. Group-1
(Normal) and group-3 (DEX only) were never challenged with the parasite and,
therefore, did not shed oocysts. Group-2 (Cp only) and group-4 (DEX + Cp) were all
shedding by day 3 p.i. However, by day 7 p.i. all mice in group-2 had ceased oocyst
shedding and remained negative for parasites throughout the experiment. All mice in
group-4 continued to shed oocysts until the experiment was terminated. Figure 2 shows
the oocyst shedding intensity of group-4 observed throughout the 4-month experiment.
There was a steady increase in oocyst shedding until the DEX regimen was altered at 8
weeks p.i. As a result of the decrease in immunosuppression, the shedding intensity also
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decreased rapidly . As the DEX-immunosuppression regimen was again instituted, there
was another steady increase in oocyst shedding until the end of the experiment.
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Figure 2. Pilot study of oocyst shedding intensity in dexamethasone-immunosuppressed
mice with Cryptosporidium parvum.

On the day of sacrifice, individual mouse spleens were weighed and recorded as a
representation of the overall immune status of the animal (Table 5). There was a
significant decrease between the spleen weights of group-3 and group-4 when compared
·to both group-! and group-2. Mice receiving DEX had depleted lymphoid follicles in the
spleen compared to mice not receiving DEX. Histological observations of spleens from
DEX-treated mice exhibited atrophy of both immature and mature lymphocytes. The
spleen weights of mice receiving DEX-immunosuppression (group-3 and group-4)
declined steadily from a mean of approximately 70 mg when the experiment began, to 20
mg at 4 weeks postimmunosuppression.

The spleen weights from these two group s
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remained at approxiamtely 20 mg until the DEX was reduced to dosing every other day.
During the period of time when the DEX was given every other day, mice from group-3
had a peak mean spleen weight of 30 mg and mice from group-4 peaked at 50 mg. When
the DEX was again administered daily, spleen weights from both DEX-treated groups
dropped to a mean of approximately 20 mg.
Throughout the experiment, the body weights of the mice were also monitored;
these data are recorded in Table 5. With respect to body weight, group-3 had a
significantly (P S 0.01) lower body weight compared to group-2, and group-4 was
significantly (P S 0.01) lower when compared to groups 1, 2, and 3. Altering the DEXimmunosuppression from daily to every other day injections did not have a significant
effect on the body weights of the mice.

Table 5. Pilot study of spleen and body weights of mice infected with Cryptosporidium
parvum represented as mean ± SE.

Spleen Weight (mg)•

Body Weight (g)•

Group

n

I (Normal)

8

68.8 + 4.0

20.5 + 1.2

2 (Cp only)

12

81.7 ± 2.7

22.3 ± 0.4

3 (DEXonly)

17

31.2 ± 5.8bc

19.4 ± 0.7c

4 (DEX + Cp)

14

32. 1 ± 4.1bc

15.7 ± 0.8bcd

• values represent those data obtamed on day of sacnfice.
b difference compared to group-! is significant (P :s 0.01).
c difference compared to group-2 is significant (P :s O.QI ).
d difference compared to group-3 is significant (P :s 0.01).

The results of the tissue localization by cryptosporidia are presented in Table 6.
Parasites were detected in the gallbladder as early as 2 weeks p.i. and the infection was
intermittent throughout the experiment. Three mice had parasite colonization in the
gallbladder; two with a score of I+ and one with a score of 4+ (refer to the Materials and
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Table 6. Pilot study of histologic location of Cryptosporidium
dexamethasone-immunosuppressed mice with a chronic infection.

parvum in

Week Postinfection at Necropsy•
2(~t;3)

TISSUE

4(n=2)

(!(n=2)

8(n=4)

12(n=l)

14(n=I)

l(!(~t;l)

NE

NE
+
+
+

Heart
Liver
Gallbladder
Kidney

+c

+c

+

Uterus
Lungs
Stomach
Pancreatic ducts
Duodenum
Jejunum
Ileum
Cecum
Colon
8

b
c
d
•
-,

+c
NE
+c
+
+
+d
+d

NE
+c
+c
+
+c
+c

+c
+

+b
+c
+d
+
+·
+d

+
+

+
+

no mice were sacrificed on week 10 p.i.
one of the mice sacrificed on week 8 p.i. was not examined and one was (-) for C. parvum.
only one of the total mice examined for the week indicated was(+) for C. parvum.
two of the total mice examined for the week indicated were(+) for C. parvum.
three of the total mice examined lOr the week indicated were (+) for C. parvum.
C. parvum absent;+, C. parvum present; NE, not examined.

Methods for a description of the scoring scale). There was no correlation between length
of infection and infection intensity in the gallbladder. One mouse had parasite
colonization in the lung (score = I+) at 2 weeks p.i., while none of the other mice
exhibited respiratory infections throughout the remainder of the experiment. The
pancreatic duct of two mice at 8 weeks p.i. had detectable parasites, both with a score of
1+ .

Microscopic examination of the intestinal tract, including duodenum, jejunum,
ileum, cecum and colon, indicated that the ileum, especially the terminal ileum, was the
most heavily infected section. The terminal ileum (T. ileum) is defined here as a 2-cm
tissue section taken proximal to the ileal-cecal junction. Parasite intensity decreased
proximal and distal with respect to the ileum and terminal ileum as demonstrated in Figure
3. Figure 3 is a pooled representation of all mice in group-4 (n = 14) sacrificed during
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the 4-month experiment. Parasite colonization in the ileum and tenninal ileum, as
determined by the mean number of organisms in each intestinal section, was significantly
(P

~

0.01) higher when compared to the duodenum, jejunum, cecum, and colon.
There appeared to be a correlation between the infection intensity in the ileum and

the oocyst shedding intensity in the feces. Figure 4 illustrates the parasite colonization
detected in the ileum throughout the 4-month experiment. Altering the DEX regimen at 8
weeks p.i. resulted in similar tissue and fecal intensity patterns as is apparent when
comparing the parasite colonization in the ileum (Figure 4) to the oocyst shedding pattern
in the feces (Figure 2).
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T. ileum

Cecum

Colon

Figure 3. Pilot study of a pooled representation of Cryptosporidium parvum colonization
in the intestinal tract of mice (group-4) with a chronic infection. *indicates significance
(P ~ 0.01) when compared to duodenum, jejunum, cecum, and colon.
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Figure 4. F'ilot study of Cryptosporidium parvum colonization in the ileum of mice
(group-4) with a chronic infection.

Pathologic findings associated with infection were isolated to the intestinal tract.
Parasite colonization at extraintestinal sites, including the gallbladder and pancreatic
ducts, did not result in any significant lesions. Heavy C. parvum infections in the ileum
and terminal ileum produced villous atrophy, crypt hyperplasia, and light to modest
inflammatory infiltration in the lamina propria. Figure 5 shows t.lte parasites at the
microvillar surface in a mouse terminal ileum at 2 weeks p.i. Figures 6 and 7 depict
some of the salient features associated with a chronic infection, namely villar fusion and
stunting, respectively. As the infection progressed, the parasite was found deep within
the intestinal crypts resulting in hyperplasia (Figure 8).
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Figure 5. Photomicrograph of Cryptosporidium parvum (arrows) colonizing the
terminal ileum of a mouse at 2 weeks postinfection (400x).

Figure 6. Photonricrograph of a mouse terminal ileum at 4 weeks postinfection
showing Cryptosporidium parvum-induced villar fusion (IOOx).
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Figure 7. Photomicrograph of a single intestinal villus from a mouse ileum
canonized by Cryptosporidium parvum (arrows). The villus has been shortened
(stunted) due to colonization by the parasite (I OOOx).

Figure 8. Photomicrograph of numerous Cryptosporidium parvum (arrows)
colonizing a hyperplastic crypt of a mouse terminal ileum at 14 weeks
postinfection (40(lx).
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A follow-up to the pilot study was performed with modifications as described in the
Experimental Design section . This experiment was designed to further characterize
chronic cryptosporidiosis in a murine model. To prepare for the unexpected mortality
that was experienced in the pilot study, animal numbers were increased as described in
the experimental design. Table 7 shows the mortality (mice that died as opposed to being
sacrificed) of the mice during the 4-month period. None of the mice from group-! died .
Only one mouse from group-2 died during the second week of the experiment and had a
very low original body weight compared to the other mice. Therefore, group-! and
group-2 are not represented in Table 7. The majority (95%) of the mice receiving DEXimmunosuppression without being challenged with C. parvum (group-3) remained active
throughout the entire experiment. Aggressive activity began to decline in this group at
approximately six weeks post-immunosuppression. At this time, hair coats of some of
the mice appeared dull. Loss of skin turgor and clinical signs of emaciation were
observed. Four mice from this group died during the fourth month of the experiment.
Group-4 (mice receiving DEX i.p. +C. parvum) and group-5 (mice receiving DEX
orally+ C. parvum) were compared on the basis of mortality, oocyst shedding intensities
and tissue colonization. Six mice from group-4 were still alive by the end of the 4-month
experiment whereas all mice from group-5 died by the end of the third month p.i.
Twenty-four (48%) of the mice in group-4 died prematurely (before being sacrificed)
compared to 29 (61.7%) of the mice that died prematurely from group-5. Mice in both of
these groups exhibited clinical signs of dehydration and anorexia as early as 2 weeks p.i.
Other signs included icterus, wasting, and abdominal distention. Mice in group-5
exhibited much more acute deterioration compared to the more chronic deterioration
observed in group-4.
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Table 7. Mortality of mice in groups 3, 4, and S during the 4-month follow-up study of
chronic cryptosporidiosis represented as deaths per week and percent death.
Group-3
Group-4
Group-S
(DEX only)
(DEX+Cp)
(DEX + Cp)•
Week Deaths/ Percent Deaths/ Percent Deaths/ Percent
Week Death
Week Death
P.i. Week Death
I
0
0.0
0
0.0
I
2.1
0
2
0
0
0
0
0
3
4
0
0
0
s
0
0
0
0
0
I
4.3
6
12.0
0
7
0
6
0
22.0
2
8.S
8
s
30])
4
9
0
13.9
3
10
0
4
34.0
38.0
9
11
0
0
9
S3.2
12
0
1
40.0
4
61.7
13
0
0
_ _14_
1
1.8
4
~~0
'
]
-0-1-31S
7.
16
0
0
Total
4
24
7.3
48.0
29
61.7
• mice in group-5 received DEX in drinking water (8JJ.g/ml).
p.i. , postinfection with C. parvum oocysts.
- indicates all mice had succumbed to infection/immunosuppression.

The oocyst shedding intensities in mouse feces were monitored on a weekly basis.
The nonnal mice (group-!) as well as the DEX treated mice (group-3) remained negative
for oocyst shedding throughout the experiment, ruling out cross-contamination by the
parasite. Approximately 80% of the mice infected with C. parvum (group-2, group-4,
and group-S) began shedding oocysts by day three p.i. By day 4 p.i., 100% of the mice
in groups-2 and 4 were shedding oocysts. All mice in group-S were shedding by day 6
p.i. , indicating a delayed prepatent period in this group. The mice in group-2 (Cp only)
ceased shedding by the end of the first week p.i. and remained negative for detectable
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parasites throughout the remainder of the experiment. Figure 9 shows the oocyst
shedding pattern for group-4 and group-S.
At the time of sacrifice, spleens were weighed as a general representation of the
immune status of the mice. Spleen weights, along with the mouse weights, are shown in
Table 8 as means± SE. The number of mice (n) for groups 3, 4, and S represented in
Table 8 shows a discrepancy from the (n) shown in Table 2 of the experimental design
because some mice died before spleens and final body weights could be collected.

Table 8. Follow-up study of spleen and body weights of mice chronically infected with
Cryptosporidiwn parvwn represented as mean± SE.

Spleen Weight (mg)•

Body Weight (g)•

Group

n

I (Normal)

10

66.0 + 3.4

20.S + 1.0

2 (Cp only)

20

69.S + 3.2

20.4 ± 0.6

3 (DEX only)

46

26.3 ± 1.5bc

20.6 + o.s

4(DEX +Cp)

46

25.9 ± 1.6bc

18.7 ± 0,4cd

S (DEX +Cp)f

43

29.8 ± 4.0bc

17.3 ± 0,4bcde

• values represent !hose data obtamed on day of sacnfice.
b difference compared to grou!>' I is significant (P s 0.01 ).
c difference compared to group-2 is significant (P s 0.01).
d difference compared 10 grou!>'3 is significant (P s 0.01).
• difference compared to group-4 is significant (P S 0.05).
f mice received DEX in drinking water (811g/ml) as opposed 10 inuaperiiOneally.

Microscopic examination of infected tissues showed similar findings as those
described in the pilot study. Histological sections of the gastrointestinal tract had
significantly higher parasite colonization in the ileum and terminal ileum when compared
with the duodenum, jejunum, cecum, and colon. Intestinal parasite colonization on a
bimonthly basis is shown in Figures lOA and JOB for group-4 and group-S,
respectively. Group-4 had fewer detectable parasites in the duodenum, jejunum, cecum,
and colon compared with the colonization of the same sections in group-S .
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Figure 9. Oocyst shedding intensities comparing mice immunosuppressed with dexamethasone
(DEX) administered intraperitoneally (i.p.) and orally (p.o). All mice receiving DEX orally died by
week 12 postinfection with C. parvum.
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Figure II is a pooled comparison for groups 4 and 5, of C. parvum organisms
detected in the intestinal sections throughout the entire experiment Again, the ileum and
terminal ileum were the most heavily parasitized with the intensity of infection decreasing
significantly (P::;; 0.01) both proximal and distal . Group-5 had a significantly (P::;; 0.05)
higher colonization in the duodenum, jejunum, and colon when compared to group-4.
The infection in group-5 was more heavily disseminated throughout the intestinal tract
compared to group-4. No parasites were observed in the cecum of group-5 and very few
were detected in the cecum of group-4. All cecal sections from group-4 were disected
from the ileal-cecal junction, whereas cecal sections from group-5 were from the tip of
the cecum.
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Figure II . Pooled intestinal colonization by Cryptosporidium parvum comparing mice
immunosuppressed with dexamethasone (DEX) administered intraperitoneally (i.p.) and
orally (p.o.). * indicates a significant difference when compared to group-4 (DEX i.p. +
Cp) for each respective tissue section (P::;; 0.05).
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Throughout the experiment, parasites were detected in the gallbladder (Figure 12)
and pancreatic ducts (Figure 13). Most of the mice examined demonstrated normal
(noninfected) pancreatic and hepatobiliary systems. In group-4, five mice had C. parvwn
in the gallbladder with a score of I+ and one mouse had C. parvwn in the pancreatic duct
with a score of 2+. In group-5, two mice had C. parvwn in the gallbladder, one with a
score of I+ and the other with a score of 2+. A total of six mice in group-5 had parasites
in the pancreatic duct with two scoring 1+, three scoring 2+ and one scoring 3+. For a
description of the scoring scale, see Materials and Methods.
Histopathologic findings were similar to those observed in the pilot study. Gross
observations at necropsy included hyperemia and distension of the terminal small
intestine and colon. Microscopically, the upper small intestine, cecum, and colon were
normal. Villi of the ileum and terminal ileum were blunted and thickened, especially as
the infection progressed. Heavy parasite colonization was associated with villar fusion
and infiltration of the lamia propria with large numbers of neutrophils. Crypts were
hyperplastic, deepened, and lacked paneth cells, a finding that has been described
previously (123).
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Figure 12. Photomicrograph of Cryptosporidium parvum (arrows) colonizing the
gallbladder of a mouse with a chronic infection (1000x).

Figure 13. Photomicrograph of Cryptosporidium parvum (arrows) colonizing the
pancreatic duct of a mouse with a chronic infection (1 OOOx).
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Effects of Cryptosporidium parvum and Dexamethasone on B and T
Lymphocyte Proliferation. Lymphocyte functionality following DEXimmunosuppression and C. parvum inoculation was determined by examining the
blastogenic response of B lymphocytes and T lymphocytes to the mitogens LPS and
ConA, respectively. The optimal concentration of both mitogens, as determined by the
stimulation induced in normal spleen cells, was 2.5 Jlg/ml. However, the difference
between the concentrations was not significant and all three concentrations for both
mitogens are reported for the purpose of emphasizing trends. Proliferative response is
represented as mean counts per minute (CPM) as described in the Materials and Methods.
Figure 14 illustrates the blastogenic response of B lymphocytes to the mitogen LPS
at 1 week (Fig. 14A) and 2 weeks (Fig. 14B) p.i. There was no statistical significance
between groups 2-4 (Cp only, DEX only, and DEX + Cp, respectively) when compared
to group-1 (Normal) for the frrst week p.i. with the exception of group-3 at 2.5 Jlg/ml
LPS (P

~

0.05). For week 2 p.i., there was a significant (P

~

0.05) difference when

comparing group-3 to group-1 at the lowest LPS concentration. Also, at 2 weeks p.i.
there was a significant (P

~

0.05) difference between group-4 and group-1 at 5 Jlg/ml

LPS and a highly significant (P

~

0.01) difference between group-4 and group-1 at 2.5

Jlg/ml LPS. Group-3 had a significantly (P

~

0.05) lower blastogenic response at 2

weeks p.i. compared to 1 week p.i. at 10 Jlg/ml LPS.
The blastogenic response ofT lymphocytes to ConA at 1 week (Fig. 15A) and 2
weeks (Fig. 15B) p.i. is shown in Figure 15. Again, there was no statistical significance
between any of the groups at 1 week p.i. However, at 2 weeks p.i. there was a
significant (P

~

0.05) difference between groups 3 and 4 when compared to both groups

1 and 2 at 2.5 Jlg/ml ConA. Group-2 had a significantly (P

~

0.05) higher blastogenic

response at 2 weeks p.i. at 2.5 Jlg/ml ConA compared to the response at 1 week p.i.
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Figure 14. Lipopolysaccharide-induced incorporation of tritiated thymidine by
mouse splenocytes expressed as counts per minute (CPM) and standard error of
the mean (error bars). Fig. 14A represents results at I week posrinfection and
Fig. 14B represents results at 2 weeks postinfection. * indicates difference
compared to normal controls is significant at P $ 0.05 whereas ** indicates
difference compared to normal controls is significant at P $ 0.01. L1 indicates
difference compared to same treatment group at 1 week postinfection is
significant (P $ 0.05).
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Figure 15. Concanavalin A-induced incorporation of tritiated thymidine by
mouse splenocytes expressed as counts per minute (CPM) and standard error of
the mean (error bars). Fig. 15A represents results at I week postinfection and
Fig. 15B represents results at 2 weeks postinfection. * indicates difference
compared to normal controls and group-2 (Cp only) is significant (P S 0.05). t.
indicates difference compared to same treatment group at I week postinfection
is significant (P s 0.05).
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Effects of Dehydroepiandrosterone on Oocyst Shedding Intensities of
Mice Infected with Cryptosporidium parvum. Originally, 51 mice were DEXimmunosuppressed, infected with JQ6 oocysts/mouse, and continued on DEXimmunosuppression. However, one mouse died 5 days postimmunosuppression and
thineen more died following C. parvwn inoculation before DHEA or DHEAS treatment
began. Nine of the 13 mice died within the first week following parasite challenge as a
resu lt of a punctured esophagus (confirmed by necropsy) which occurred during C.
parvum intragastric inoculation. Consequently, only 37 mice were used in the final

study.
Table 9 shows the number of mice that died from each treatment group during either
weeks I, 2, 3, or 4 posttreatment with DHEA or DHEAS. The remaining mice were
sacrificed at the end of the 4-week treatment period. Some of the routes and dosages of
DHEA and DHEAS appeared to be toxic, as determined by monality.

Table 9. Number of mice in each treatment group that died per week during four weeks
of deh ydroepiandrosterone (DHEA) or dehydroepiandrosterone-sulfate (DHEAS)
treatment for chronic cryptosporidiosis.
Vehicle fRoute
Peanut Oil (o.o.)
Proovlene Glvcol (s.c.)
Sterile Water (s.c.)
Week Control 50 j.J.g 150 j.J.g 300 j.J.g 3 mg 6mg 12mg
3 mg
6 mg
12mg
DHEA
DHEA
DHEA
DHEA
DHEA DHEA
DHEAS DHEAS DHEAS
P.T•
I
0
0
I
4
2
I
0
0
0
2
2
0
I
I
0
0
3
0
I
I
0
0
0
0
3
0
0
0
0
4
0
0
3
0
2
3
2
Total
I
4
4
4
4
0
I
3
3
3
a P .T., posttreatment with DHEA or DHEAS; p.o =per os; s.c. = subcutaneous.
-indicates all mice in the respective group succumbed to lrea!ment.
DHEA = dehydroepiandrosterone; DHEAS = DHEA-sulfate.
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Following parasite challenge, mice from all groups were randomly sampled on a
daily basis to ensure that all mice had C. parvum infection before DHEA or DHEAS
treatment began. The number of detectable oocysts in all treatment groups (including
controls) varied considerably throughout the experiment, a common finding with C .
parvum oocyst shedding.

The shedding intensities in the mice treated with DHEA (50, 150, or 300 IJ.g) orally
in a peanut-oil vehicle (Figure 16) showed no significant decrease when compared to
controls. Ironically, the mice treated with 300 IJ.g of DHEA had a significantly (P S
0.01) higher shedding intensity on day 14 of treatment when compared to controls.
Moreover, there was a significant (P S 0.05) increase in oocyst numbers detected on day
24 of treatment when mice receiving 50 IJ.g DHEA were compared to controls.
In mice treated s.c. with DHEA (3, 6, and 12 mg) suspended in propylene glycol
(Figure 17), there was no significant decrease in the oocyst shedding intensities when
compared to the control mice. There was, however, a significant (P S 0.05) increase in
shedding intensity in mice that received 6 mg DHEA compared to controls on day 14 of
treatment. By this time, all mice receiving 3 and 12 mg DHEA had died. The propylene
glycol vehicle was tissue toxic at the site of injection, resulting in scab formation and
open sores as early as day 3 posttreatment. When the mice were necropsied following
death or sacrifice, local deposits of DHEA were found under the skin near the injection
sites of mice receiving 6 mg and 12 mg DHEA. Similar findings were reported by Loria
et al. (67) when DHEA was administered s.c. in a suspension of dimethyl sulfoxide,
suggesting that this local accumulation may lead to prolonged DHEA interaction with the
lymphoid system.
The mice treated s.c. with DHEAS (3 , 6, and 12 mg) in deionized water also failed
to show any significant decrease in shedding intensity compared to control mice (Figure
18).
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Figure 18. Oocyst shedding intensities of control mice compared to mice treated
therapeutically with 3, 6, or 12 mg of dehydroepiandrosterone-sulfate administered
subcutaneously in 250 Jll of a sterile, deionized water vehicle.

As demonstrated in Table 9, two of the three mice receiving 12 mg of DHEAS died I day
following treatment and the remaining mouse died I week later, suggesting possible
DHEAS toxicity at this dosage. All mice receiving 3 and 6 mg DHEAS survived until the
fourth week of treannent, with the exception of one mouse receiving 6 mg which died
during the second week of treatment.
At sacrifice, mice were examined internally and externally for gross abnormalities.
Those mice receiving DHEA or DHEAS had almost no fatty deposits around their
kidneys and tenni nal colon. In contrast, the control mice had large accumulations of fatty
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material at both of these sites, which is a common finding in mice receiving prolonged
GC therapy.
At the time of sacrifice, spleens were collected and weighed as a general
representation of the immune starus of the mice. Table I 0 presents the average spleen
and body weights of each respective group at the time of sacrifice. Groups-3b and 4a
had significantly higher spleen weights when compared to group- I (P
3a (P !> 0.01). Group-3b also had a significantly (P

~

~

0.05) and group-

0.05) higher spleen weight

compared to group-3c. Furthermore, group-2b were the only mice with body weights
significantly (P

~

0.05) lower than group- I.

Table I 0. Spleen and body weights of control mice and mice treated therapeutically with
dehydroepiandrosterone (DHEA) or dehydroepiandrosterone-sulfate (DHEAS) for
chronic cryptosporidiosis.
Group

n

Treatment (dose)

Route

I

4

None (controls)

None

2a

4

DHEA

2b

4

DHEA (150 Ill!:)

jl.O.

~1!:)

p.o.

(50~g)

p.o.

2c

4

DHEA (300

3a

4

DHEA(3mg)

S.C.

3b

4

DHEA(6mJ!:)

S.C.

Spleen Weill:ht (mil:)•

± 4.8
32.5 ± 4.8
25.0 ± 5.0
27.5

Body Weight (g)•

± 0.8
17.1 ± 1.2
13.6 ± 0.6b
17.2

26.9 + 2.4

17.1 + 0.8

± 4.1
45.0 ± IJ.9bcd

16.5

16.6 + 0.7

20.0

17.2

3c

4

DHEA (12mll:)

S. C.

20.0 + 7.1

4a

3

DHEAS (3mg)

S.C.

50.0 ± )J.5bC

15.4

4b

3

DHEAS (6mg)

S.C .

16.3

4c

3

DHEAS (12 mg)

S .C.

± 8.7
27.5 ± 0.0
35.0

± 0.3
± 1.9

± 0.2
± 0.6
15. 1 ± 0.2

• values represent those data obtamed on day of sacnfice.
b difference compared to group- I is significant (P S 0.05).
c difference compared to group-3a is significant (P $ 0.01).
d difference compared to group-3c is significant (P S 0.05).
p.o =per os; s.c = subcutaneous; DHEA = dehydroepiandrostcrone; DHEAS = DHEA-sulfate.
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DISCUSSION
Characterization of Chronic Cryptosporidiosis in Immunosuppressed
Mice. The results of the present study suggest that the DEX-immunosuppressed
C57BU6N mouse will provide a reliable laboratory animal model for evaluating chronic
C. parvum infections. The utility of DEX as an effective immunosuppressent inducing

susceptibility to C. parvum has been supported by Rasmussen et al. (92, 94) and Rheg
et al. (98). Furthermore, the adult C57BU6N mouse has been described previously as
being susceptible to C. parvum following immunosuppression (92). Our results show
that the C57BU6N mouse can be successfully immunosuppressed with DEX, be infected
with C. parvum oocysts, and maintain an infection for atleast4 months. The chronicity
of the infection was detennined by evaluating infection intensity as represented by oocyst
excretion in the feces, parasite distribution in the tissues, and parasite induced-pathology.
The infection intensity was very sensitive to the amount of DEX administered, a
finding that has been reported previously (98). As the DEX regimen was reduced from
daily dosing to dosing ever other day, the infection intensity decreased rapidly (Figure 2).
This indicates that I) the DEX was rapidly removed from the circulation of the mice, and
2) the immune system was not totally ablated by the first 2 months of DEX
administration. The idea that DEX was removed quickly from circulation would need to
be confmned by specific assays used to determine plasma levels and excretion rates of
DEX over a given time interval in this particular animal model. These assays were not
carried out in the present study and merit further investigation. The decrease in DEX that
was administered and consequent reduction in infection intensity emphasizes the
important role DEX plays in a properly immunosuppressed mouse model for studying
chronic cryptosporidiosis.
The presence of high levels of DEX in the circulation stimulates the synthesis of
excess concentrations of corticosteroid binding globulin (CBG) (70). This protein
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globulin binds with very high affinity to GC's in the blood, thus inhibiting the migration
of the GC's to their target tissues. Since only unbound GC's readily gain access to their
target tissue receptors, the elevated CBG levels not only make it possible to have high
circulating GC's without incurring toxic effects, but also increase the availability of the
GC's for degradation by the liver.
Specifically, DEX is known to be an inducer of the cytochrome P-450 system in
liver cells, which is responsible for the detoxification and degradation of foreign
substances like exogenous drugs (17) such as DEX. The P-450 system convens the
lipid-soluble DEX into a water-soluble substance that has little or no biological activity
(70). This substance is then readily excreted via the bile and/or urine.

Funhermore,

because the P-450 system was activated by the DEX and the liver cells had an increased
capacity to degrade the DEX, it is not surprising that when the DEX-administration was
decreased, the efficiency of the P-450 system resulted in a rapid clearance of the DEX
from the mice.
The half-life of DEX is significant when considering excretion rates in different
hosts. Studies in mammals immunosuppressed with DEX suggest a half-life of 3 to 9
hours, with a duration of action lasting up to 72 hours (20, 51). The shon half-life
suppons our findings that the DEX was rapidly excreted when given every other day. It
also indicates that under the conditions of the present study, administering DEX at 125
~g/mouse/day

on a daily basis was an appropriate regimen for inducing a chronic

infection without inducing acute signs of toxicity.

If one intends to examine

cryptosporidiosis over an extended period (4 months) in the C57BU6N mouse model, it
is recommended that the initial dose of DEX be decreased rather that altering the amount
in the middle of the experiment Funher studies in our laboratory suggest that decreasing
the DEX dosage may yield more optimal results and thus increase the utility of this animal
model for evaluating chronic cryptosporidiosis.
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It is probable that the chronic use of DEX does not totally destroy the host's

immune system. This is an important consideration when attempting to relate this mouse
model to individuals harboring C. parvum who also have AIDS or are receiving
chemotherapy. The mice in the present study were able to reduce the oocyst shedding
intensity and the parasite colonization in the tissues when the DEX was decreased
(Figures 2 and 4). This fmding indicates that the immune cell populations responsible for
clearing C. parvum infections were still able to be restored once the immunosuppressive
effects of DEX were decreased. This suggests promise for AIDS patients and other
immunocompromised individuals exhibiting fulminate cryptosporidiosis. In these
patients, the use of immunomodulators to boost the immune system may facilitate a
decrease in intensity and/or a more rapid clearance of the infection. The infection
intensity in human hosts harboring C. parvum is dependent upon the immune status of
the host. Patients receiving exogenous immunosuppression and .exhibiting chronic
cryptosporidiosis quickly cleared the infection once the source of immunosuppression
was withdrawn (39). Because of the inhibitory effects DEX has on antigen presentation
by the macrophage and lymphocyte proliferation, it is likely that when the
immunosuppression is removed or decreased, the cascade of events associated with
antigen presentation is reinitiated (51).
The cascade of events inhibited by DEX includes the release of interleukin-1 (IL-l)
and tumor necrosis factor from macrophages, the release of interleuk:in-2 (IL-2) and
gamma-interferon from activated T lymphocytes, and the actions of migration-inhibitory
factor (MIF) and gamma-interferon on macrophages (51). Previous studies suggest an
important role for T lymphocytes, IL-2, and gamma-interferon in fighting
cryptosporidiosis (55, 75, 122, 123). A decrease in exogenous immunosuppression as
was seen in the present study, and the subsequent decrease in oocyst shedding intensity
and tissue colonization by C. parvum, correlate well with previous findings describing
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the interrelationships between immune status and persistent C. parvum infections in
animals and humans. Our findings agree with other research which has shown that if the
source of immunosuppression is removed or overcome in patients with chronic
cryptosporidiosis, the infection intensity decreases (39, 98).
We used spleen weights as a general representation of the overall immune status of
the mice. In a recent study, Pabst et al. (89) found that more lymphocytes migrate to the
spleen than any other lymphoid organ. Whether or not there is a direct correlation
between spleen weights and immune status of the host has not been described to our
knowledge. We found that the more active mice were those that generally had the largest
spleens, which indicates a possible correlation between overall health status and spleen
weights. Our observations also suggested that the mice with the greatest oocyst shedding
intensities and tissue colonization by C. parvum had the smallest spleens. In both the
pilot and follow-up studies examining chronic cryptosporidiosis, mice challenged with C.
parvum without being immunosuppressed had the greatest spleen weights at the time of

sacrifice. Although the difference compared to normal mice was not significant, it
indicates that C. parvum may be initiating an active immune response by the nonimmunosuppressed host, resulting in an increase in lymphocyte numbers. This response
may be useful in identifying the immune parameters important for inducing resistance to
C. parvum or in examining a latent infection. Relating this response to the function of

memory cell involvement in inducing resistance is another area requiring further
investigation. An increase in immune status was also evident as was determined by the
spleen weights of mice sacrificed before, during, and after the DEX regimen was altered.
The mice receiving DEX alone and mice receiving DEX and C. parvum challenge had a
1.5-fold and a 2.5-fold increase in spleen weight, respectively, when the DEX was
reduced. Although specific lymphocyte populations responsible for the increased spleen
weights were not assessed, studies using immunomodulators to boost immune
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parameters in mice infected with C. parvum have demonstrated a significant increase in
total T lymphocyte populations in the spleen (unpublished data). This finding further
emphasizes the protective importance of the CMI branch of the immune system in
cryptosporidial infections. Because the C57BU6N mouse has a fully intact immune
system, using this mouse as a model for chronic cryptosporidiosis would readily facilitate
the elucidation of specific immune responses involved in resistance to cryptosporidiosis.
The body weights of the mice in the pilot and follow-up studies were compared as
was the overall appearance and activity of the mice. Normal mice and mice challenged
with C. parvum without DEX-immunosuppression had a gradual increase in body weight
throughout the experiments. Mice in these two groups remained active and were quite
aggressive when handled. Mice immunosuppressed with DEX and challenged with C.
parvum were more unhealthy and less active when compared with the other treatment

groups. The body weights of DEX-treated mice (with or without C. parvum) were
generally lower than the body weights of non-DEX-treated mice, but this observation
was not always the case (Tables 5 and 8). When mice were initially immunosuppressed,
their overall body weights decreased by approximately 20% (3 to 4 grams) during the
first 2 to 3 weeks of immunosuppression. Toward the end of the experiment, particularly
in the follow-up study, mice receiving DEX without C. parvum had body weights
comparable to normal controls. This increase in body weight was attributed to obesity
and water retention induced by the DEX and was not an indication of increased health
status. Chronic DEX administration resulted in accumulation of fat deposits in the face,
neck, and peritoneal cavity of the mice. This finding is described as a common side
effect of long-term, high-dose DEX-immunosuppression in mammals, causing a
condition known as Cushing's Syndrome (70). As a consequence, some of the mice
receiving DEX had larger body weights due to excess accumulation of fat. Mice that
received DEX and C. parvum maintained significantly lower body weights throughout
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the study when compared with the other treatment groups. This indicates that the
presence of the parasite in an immunosuppressed host, rather than the
immunosuppression alone, results in deterioration of the mice. Mice with DEX and C.
parvum had very little fat deposition compared to mice treated with DEX alone. The
DEX-treated mice infected with C. parvum were more anorexic and their fat deposits
were probably depleted by the energy expended in combating the parasitic infection.
The route of DEX-administration (intraperitoneal vs. oral) yielded different results
with respect to animal health, mortality, infection intensity and tissue colonization.
Intraperitoneal administration (125 J.lg/mouse/day) and oral administration (8 J.lg/ml in the
drinking water ad libitum) were both successful in inducing susceptibility to C. parvum
after 12 days of immunosuppression. The DEX administered i.p. was the only route
successful in maintaining a 4-month chronic infection once the mice were inoculated with
infective oocysts, as determined by excretion of oocysts in the feces and tissue
colonization by the parasite (Figures 2, 9 and 10; Table 6). Monitoring clinical signs and
examining shedding intensities in the feces were possible for a longer period of time
when DEX was administered i.p. Moreover, a more consistent shedding pattern in mice
given DEX i.p. over a longer course of infection will enable better delineation and
characterization of therapeutic interventions under the experimental conditions employed
in this study. The utility of administering DEX i.p. in the assessment of chronic
cryptosporidiosis is further supported by the lack of significant evidence indicating
toxicity following chronic therapy (Table 7). Follow-up studies in our laboratory have
shown that fewer than 12 days of i.p. DEX administration are required to induce
susceptibility to C. parvum in this mouse model (unpublished data). These findings
support the C57BL/6N mouse model for its use in screening therapeutics. Continuing
studies in our laboratory are examining different formulations and routes for
administering DEX to this mouse model.
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Daily i.p. injections are labor intensive and cause undue stress to mice which may
result in stress-i nduced immunosuppression. Oral administration of the DEX was
assessed in the present study as a possible alternative to i.p. administration. Oral
administration of DEX to induce susceptibility to C. parvum in rats has been described
previously (94, 98). It is much more practical and less time consuming to administer the
DEX orally. The majority of human patients receiving DEX-induced immunosuppressive
therapy are administered DEX orally because the drug is resistant to degradation by the
intestinal enzymes (5 I). Oral DEX administration resulted in higher numbers of parasites
detected in sections of the duodenum, jejunum, cecum, and colon (Figure 10) and an
increase in the number of mice with pancreatic infections compared to mice given DEX
i.p. The DEX given orally may have a detrimental effect directly on the intestinal
mucosa, thus making the mucosa more susceptible to invasion by C. parvum (I, 106).
Subcutaneous administration of DEX has been shown to cause an increase in bacterial
adherence to intestinal cells (I). The DEX administered orally may also destroy the
intestinal micro flora, increasing the susceptibility of the enterocytes to invasion by C.
parvum, a finding that has been previously reponed (53). Damage to intestinal mucosa

and/or destruction of intestinal flora resulting in an increase in infection intensity would
explain the increased parasite colonization in the intestinal sections and would agree with
previous findings suggesting the involvement of non-specific immune responses to C.
parvum (53). Pathologic fmdings comparing mice immunosuppressed with DEX i.p. to

mice immunosuppressed orally failed to show any significant difference in lesions or
decrease in lymphoid regions between the two groups. Cytochemical analysis of
intestinal cells from mice receiving DEX orally compared with mice receiving DEX i.p.
may funher explain the direct effects of DEX on intestinal cells.
In the present study, oral administration of DEX was associated with a number of
disadvantages. It is difficult, if not impossible, to control the amount of DEX each
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mouse receives on a daily basis. Because the mice had free access to the water and
evidence suggests that mice in the same cage drink different amounts of water
(unpublished data), it was concluded that mice in the same cage were getting different
amounts of DEX. Also, polydipsia (excessive drinking) is a common side effect of GC
administration (62). As a result, the mice would drink increased amounts DEX, the DEX
would induce more water consumption, and the mice would, in a sense, overdose on the
DEX. This could explain the acute signs of deterioration as represented by the
significantly lower body weights (Table 8) and much higher mortality rates (Table 7) over
a shoner period observed in mice receiving DEX orally . Funhermore, it is also probable
that some of the mice would drink excess DEX in the water, become moribund, have
decreased activity, and consequently decrease their water consumption. This, in tum,
would decrease the immunosuppression of the mice and the infection intensity would
rapidly diminish as is already evident from the pilot study and other studies (98).
Consequently, the mice would have such large fluctuations in infection intensity that it
would be difficult to use this type of a model in drug screening studies.
Oocyst shedding intensities were affected by the route of immunosuppression. Oral
administration of DEX was initially associated with a delay in oocyst shedding and then a
rapid increase in shedding until all mice died (Figure 9). Some mice did not begin
shedding until day 6 postinfection, indicating that it would take longer to screen drugs
using this model. fluctuations in shedding intensities yielded much higher variability
between individual mice immunosuppressed with DEX in the drinking water compared
with mice immunosuppressed with DEX i.p. To account for the variability in shedding,
and to compensate for the rapid death of mice receiving DEX orally, it would be
necessary to dramatically increase the number of mice used for a chronic study, thus
decreasing the practical use of an animal model receiving DEX in the drinking water.
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The prepatent period for C. parvum in the C57BU6N mouse model ranged from 3
to 6 days, depending upon the route of immunosuppression. A prepatent period of 3 to 6
days is similar to the prepatent period reported by Tzipori et al. (120) for neonatal mice
and rats. There appeared to be a correlation between the oocyst shedding intensity in the
feces and the parasite colonization in the ileum. The oocyst shedding pattern over time
(Figure 2) paralleled the pattern of parasite colonization in the ileum (Figure 4). This
finding supports the use of the oocyst shedding pattern as a good representation of
infection intensity.
Histopathologic findings in the C57BU6N mouse model demonstrated parasite
colonization throughout the entire intestinal tract as well as in extraintestinal sites.
Parasites were present in the upper duodenum near the pyloric ring adjacent to the mucus
secreting Brunner's glands. However, very few parasites were found in the terminal
duodenum. A similar finding involving the pyloric ring was described by Ungar et al.
(122). There may be some secretory products associated with the upper duodenum that
facilitate the survival of C. parvum in this region but not in the terminal duodenum. It
may be that the mucus secretions from the Brunner's glands or other secretory cells alter
the intestinal environment enough to allow the oocysts to excyst in the upper duodenum
and initiate the life cycle of C. parvum. It is also possible that pancreatic and/or bile
secretions released into the lumen of the duodenum create an environment compatible for
C. parvum growth because of a decrease in pH. In vitro studies have shown that C.

parvum is sensitive to pH under some conditions and resistant under others (39). The

development of a reliable in vitro culture system may help to answer questions regarding
the sensitivity of C. parvum to various environmental conditions. The jejunum was
seldom colonized heavily unless the parasites in the terminal small intestine were quite
numerous. This indicates that C. parvum may have an ability to migrate to other sites
when the competition for intestinal cells in the terminal small intestine is too demanding.
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Intestinal tropism of C. parvum in rats has been described previously (97). The ileum
and terminal ileum were the most heavily colonized intestinal sections in the present
study. Similar results in mice and rats infected with C. parvum have been reported by
others (75, 94, 98).
During the early stages of infection, C. parvum was found predominantly along the
sides and tips of the villi. As the infection progressed, more parasites were found deep
within the crypts. The parasites would destroy the epithelial cells in the ileum so rapidly
that the villi became fused and shortened, while the crypts became deeper and
hyperplastic. This ultimately resulted in a decrease in the villus-to-crypt ratio and more
parasites had access to the epithelial cells of the crypts. Villar fusion and crypt
hyperplasia were seen only in the ileum and terminal ileum, undoubtedly due to the
infection intensity in tltis region compared to other intestinal sites. The reason C. parvum
colonizes this region of the intestine in greatest numbers is not known. Anatomical
obstruction at the ileal-cecal junction may play a role, but this has not been described
previously. It may be that receptors for C. parvum are present in the intestines and are
much more numerous in the terminal small intestine compared to other intestinal sites. In
the present study numerous parasites were found associated with Peyer's patches in mice
receiving DEX-treatrnent, while fewer parasites were found more distal to the Peyer's
patches. This may be a preferred site for receptors specific for C. parvum. Intact and
partially digested C. parvum have been identified in macrophages beneath M-cells
(membrane-like epithelial cells overlying Peyer's patches) (26). Peyer's patches and
adjacent M-cells are believed to play a role in introducing C. parvum to the immune
system of the host (26, 69) .

The fact that the mice in our studies were

immunosuppressed may explain why the lymphocytes associated with Peyer's patches
and the M-cells were not functioning in the removal of C. parvum from these sites in the
ileum. The immunological response to C. parvum in the ileum may be mediated by other
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unknown factors not found in other regions of the intestines. These factors may be
immobilized by toxins produced by the parasite, enterotoxins originating in the intestines,
or by the exogenous immunosuppression, whether it be DEX, HN -virus, or some other
source (39). The phenomena regarding the immunological response to C. parvum are not
clear and deserve further investigation. This mouse model should provide a reliable
model for investigating the immune response to C. parvum.
In the two chronic studies conducted, C. parvum was found in the lungs, pancreatic
ducts, and gallbladder. Respiratory, pancreatic, and biliary involvement by C. parvum as
seen in this mouse model has been documented in humans (49, 82) and only recently in
other animal models (75, 122). Only one mouse in the present study had detectable
parasites in the lungs (Table 6). The parasites could have been inhaled during the initial
intragastric inoculation of oocysts. This finding does suggest, however, that the mouse
model as described in these studies could be beneficial in examining respiratory
infections, an important condition in AIDS patients with chronic cryptosporidiosis (82).
The presence of C. parvum in the pancreatic ducts and gallbladder indicates that the
parasite must be able to migrate to these extraintestinal sites. The mode of migration may
be mediated by mobile cells of the immune system, such as macrophages, that have
specific receptors which recognize C. parvum and facilitate transport. Furthermore, the
environment associated with pancreatic and bile secretions appears to be conducive for
the growth and development of C. parvum. This observation is based on our findings
which demonstrated large numbers of parasites associated with almost every available
epithelial cell in some gallbladder and pancreatic duct infections. An earlier study
suggests that chronic immunosuppression with GC's alters the electrolyte balance in bile
secretions, which may also play a role in creating an environment that supports C.
parvum development in the gallbladder (18).
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The DEX-immunosuppressed C57BU6N mouse shows promise as a reliable model
for studying chronic cryptosporidiosis. The pathogenesis of infection and the immune
response of the mouse can readily be examined using this model. The disease in humans
is comparable to the disease described in this mouse model in that the distribution of the
parasite in both hosts involves similar intestinal and extraintestinal sites. In AIDS
patients, histological documentation of extraintestinal cryptosporidiosis associated with
respiratory, pancreatic, and biliary infestations by C. parvum have been increasingly
reponed (50, 122). Similar findings have also been reponed in immunocompetent
patients (122). Because of the chronic infection that is established in DEXimmunosuppressed C57BU6N mice, and because of the close resemblance C. parvum
infection in this model has to human cryptosporidiosis, evaluation of possible
anticryptosporidial drugs as well as the development of a vaccine against this disease is
probable. The mouse model described herein for chronic infection will also be useful in
further defining immune defects responsible for establishment of chronic
cryptosporidiosis in patients with compromised immune systems. Funhermore, this
model can be used for the assessment of potential immunomodulators for treating chronic
C. parvum infections.

Effects of Cryptosporidium parvum and Dexamethasone on B and T
Lymphocyte Proliferation. This experiment compared normal mouse splenocytes to
the effects that DEX alone, C. parvum alone, and DEX + C. parvum had on B and T
lymphocyte functionality. The anti-inflammatory and immunosuppressive actions of
DEX are inseparably linked because they both largely result from inhibition of specific
lymphocyte functions (51).

In most instances, the effects on lymphocytes are a

consequence of g1ucoconicoid-induced inhibition of the action of lymphokines, including
IL-2 through IL-6 and gamma-interferon (22, 51).

Specific assays to determine

lymphokine inhibition were not performed in these studies and would be required for an

7 I
in depth characterization of the immune response to C. parvum. However, the
proliferative responses were assessed by the ability of splenic lymphocytes to respond to
the mitogens LPS (B lymphocyte stimulant) and ConA (f lymphocyte stimulant) at I and
2 weeks postinfection with C. parvum.

To our knowledge, no one using DEX in

rodents infected with C. parvum has looked at the immune status of the animals prior to
an earlier study done in our laboratory involving C. parvum-infected rats (94) and the
present study in C57Bl)6N mice.
In the present study, all three concentrations of LPS (10, 5 and 2.5 ~g/ml) resulted
in similar trends in proliferation. The two lower concentrations of ConA (2.5 and 1.25
~g/ml)

resulted in similar trends. The greatest stimulation (though not significant)

occurred at 2.5

~g/ml

for both mitogens. The finesse required in performing these

lymphocyte proliferation assays, as well as the lack of experience on my part, may
account for discrepancies in these results. Nevertheless, trends were observed and are
discussed herein.
Spleen cells collected from normal mice at I and 2 weeks p.i. had the greatest
proliferative response to all three LPS concentrations when compared to . the other
treatment groups (Figure 14). Lymphocytes from normal mice had the greatest response
to ConA at the two lower concentrations for the first week p.i. (Figure 15A) and the
highest and lowest concentration at 2 weeks p.i. (Figure 15B) compared to the other
treatment groups. Lymphocyte responses from groups-2, 3 and 4 (Cp only, DEX only,
and DEX + Cp, respectively) were compared for statistical significance to normal mice
(group-!). Although the difference compared to normal mice was not significant, a
general trend indicated that mice in group-2 had a decreased lymphocyte response to
mitogen stimulation. Antigen stimulation (C. parvum in this case) would be expected to
result in an increased lymphocyte response.

In our experiments, the parasite may be

inducing an immunosuppressive effect on the lymphocytes, a phenomenon that has been
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described in association with Trypanosoma

cruzi (61) .

Parasite-induced

immunosuppression, if present, may be inducing alterations in lymphocyte activation by
interfering with lymphokine production or lymphokine-receptor interactions.
Investigators have reported a decrease in IL-2 in association with the development of
chronic Trypanosoma cruzi infections in mice (61) and in association with C. parvum
infections (39). Decreased IL-2 levels have also been reported in AIDS patients with
cryptosporidiosis. Because IL-2 is important for effective lymphoproliferation in
response to antigens, a decrease in this lymphokine would result in a decreased immune
response. The use of IL-2 as a prophylactic/therapeutic agent against C. parvum
infections has been examined and has demonstrated promise as a treatment for
cryptosporidiosis (39, 123). Furthermore, C. parvum may be releasing a toxic substance
that alters the expression of surface molecules on lymphocytes. A variety of cell
membrane molecules that serve as receptors for chemicals such as IL-2 are involved in
the activation of lymphocytes, and are critical for the clonal expansion of immune cells.
It is possible that the immunosuppressive effects of C. parvum are mediated by a

secretion product that destroys membrane molecules and ultimately interferes with
lymphocyte activation. If a toxin were involved, it would indicate that the heavier the
infection (or the larger the dose of parasites ingested), the more immunosuppressed the
host would become. This could explain why the present study and others have seen a
dose-response effect with regard to the number of parasites inoculated and the immune
response of the host (9, 19). Many other immune effector mechanisms could be involved
and a more representative study examining these mechanisms is merited.
At the optimal LPS and ConA concentration

(2. 5~Lg/ml),

DEX-administration alone

significantly decreased functionality of B lymphocytes at I and 2 weeks p.i. (Figure 14)
and T lymphocytes at 2 weeks p.i. (Figure 15) when compared with normal mice. This
trend was observed with both mitogens at all concentrations, with the exception of 5
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Jlg/ml ConA at 1 week p.i. This decrease in lymphocyte response to mitogen stimulation

following DEX-administration supports findings which suggest that the mechanism of
DEX therapy involves lymphocytolysis (22, 62). In GC-sensitive species like rodents,
DEX-treatment is believed to result in an immediate lymphopenia (22). This profound
decrease in circulating lymphocytes results from cell lysis mediated by the activation of an
endonuclease which destroys cellular DNA (22). In the present study, the mice
immunosuppressed with DEX without C. parvwn challenge had lower stimulation at 2
weeks p.i. than at I week p.i. This is an expected finding if DEX results in a gradual
immunosuppression. However, as described earlier, DEX is believed to result in a
immediate lymphopenia. Mice had been receiving the DEX for 21 and 28 days prior to
spleen collection at 1 and 2 weeks p.i., respectively. If the immunosuppressive effect
due to lymphocytolysis was immediate, one would expect to fmd fewer splenocytes at 2
weeks p.i. than at 1 week p.i. Absolute lymphocyte counts were actually higher at 2
weeks p.i. than at I week p.i. in mice receiving DEX-treatment alone (unpublished data).
This indicates that even though the lymphocytes were present, their ability to respond to
mitogen had been diminished by DEX. It may be that in the mouse, a combination of
lymphocytolysis and lymphocyte redistribution results in lymphopenia. In GC-resistant
species, lymphopenia results from redistribution of lymphocytes to other lymphoid
regions (22). Studies done in rats showed that DEX treatment resulted in a significant
drop in BandT lymphocyte response to LPS and ConA, respectively (94). Additionally,
bovine lymphocyte responses to mitogens were suppressed by DEX in vivo and in vitro
and the authors suggested a selective depletion of B lymphocytes (87). In contrast, other
investigators have shown that cattle treated with DEX had an enhanced lymphocyte
response to mitogen stimulation (22). Cattle are considered GC-resistant (as are
humans), while mice are considered GC-sensitive. These contrasting observations not
only support the fact that DEX-treatment results in a diversity of effects in different

74
species, but also emphasizes the importance of using caution when extrapolating results
between species.
Mice in group-4 (DEX + Cp) had a significant decrease in B lymphocyte function at
5 (P ~ 0.05) and 2.5 (P ~ 0.01) Jlg/ml LPS at two weeks p.i. Group-4 mice also had a

significant decrease in T lymphocyte function at 2.5 J.Lg/ml of ConA at 2 weeks p.i. A
general trend of the experiment demonstrated that mice in group-4 had the lowest
stimulation compared to the other treatment groups. This experiment also demonstrated a
decrease in both B and T lymphocyte proliferation when results at 2 weeks p.i. were
compared to results at 1 week p.i. However, the difference was only significant (P

~

0.05) for group-3 at 10 J.Lg/ml LPS and group-2 at 2.5 Jlg/ml ConA. These findings
further support the hypothesis that C. parvum may be inducing its own suppressive
effects on the immune system, with the immunosuppressive effects becoming more
pronounced as the infection progresses. In patients with AIDS and other related immune
dysfunctions, cryptosporidiosis can result in death without symptomatic treatment.
Treatment resulting in an up-regulation of the humoral and/or CMI system can be
expected to prolong the life of the patient. It is still not clear as to which branch of the
immune system is responsible for clearing chronic cryptosporidiosis. It is probable,
however, that an interaction of both B and T lymphocyte functions is required to
eliminate an infection. In the present study, both BandT lymphocyte functions were
depressed by DEX alone, C. parvum alone, and DEX +C. parvum. Because of the
interactions of B and T lymphocyte populations, macrophages, cytokines, and other
factors in initiating a successful immune response, and because of the controversy
concerning this subject, further investigation of the immunological response to C.
parvum infections is paramount. The use of the C57BL/6N mouse model in further

defining the immune parameters involved in chronic C. parvum infections should be
pursued.
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Effects of Dehydroepiandrosterone on Oocyst Shedding Intensities of
Mice Infected with Cryptosporidium parvum . The therapeutic utility of the
immunomodulator DHEA was investigated for its ability to reduce chronic C. parvum
infections in C57BU6N mice. The mice were immunosuppressed with DEX and then
infected intragastrically with J()6 C. parvum oocysts. Following the establishment of a
35-day chronic infection, mice were treated with DHEA or its sulfated conjugate DHEAS
for 28 consecutive days. Infection reduction was determined by significant decreases in
oocyst shedding.
Based on the results of this experiment, the therapeutic administration of DHEA or
DHEAS had no significant effect on decreasing C. parvum infection. Our laboratory has
shown that DHEA resulted in a significant decrease in infection when administered to rats
at the same time (prophylactic) as C. parvum inoculation (94). In the present study, mice
were used as opposed to rats and the infection was allowed to progress before DHEA or
DHEAS was administered. The different animal models used (rats vs. mice) may
account, in part, for the contrasting effects observed. Moreover, the fact that the mice
were allowed to establish a chronic infection before DHEA or DHEAS therapy was
initiated is a more plausible explanation for the lack of cryptosporidial reduction. It may
be that the infection had progressed too far for DHEA or DHEAS to reverse the
immunosuppressive effects of DEX. The DHEA and DHEAS have been reported to act
by reversing glucocorticoid-induced suppression of lymphocytes (13, 16, 71, 113 ).
Rasmussen et al. (94) suggested that DHEA may act by potentiating immune parameters
suppressed by DEX. Even though an effect of DHEA or DHEAS on decreasing parasite
intensities was not demonstrated in the present study, the effect of the immunomodulators
on specific immune parameters was not assessed and requires further investigation.
The oral doses of DHEA and DHEAS selected for this experiment were within the
same range as the concentration of DEX that was used to immunosuppress the mice. The
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amount of DEX given (125 IJ.g/mouse/day) was equivalent to approximately 7 mg/kg.
Likewise, the concentrations of oral DHEA (50, 150, and 300 IJ.g/mouse/day) were
equivalent to 2.7, 8.3, and 16.6 mg/kg, respectively. The amount of DEX administered
(7 mg/kg) was within the range of the three DHEA concentrations (2.7 to 16.6 mg/kg).
If DHEA is an antagonist of DEX (competing for the same receptor), then an effect may
be expected if both drugs were given at approximately equivalent doses. However,

recent evidence suggests that although DHEA is an anti-glucocorticoid, it is not an
antagonist of DEX because it utilizes its own receptors (76).
If DHEA truly acts as an anti-glucocorticoid in up-regulating the immune system,
decreased cryptosporidial activity may be more readily observed if both drugs (DEX and
DHEA) are administered via the same route. In this study, DEX was administered i.p.
and DHEA was administered orally. The route alone may have such a dramatic effect on
bioavailability that little DHEA had access to its effector tissues, which would have
decreased its immunomodulator effect. The route of administration not only affects the
bioavailability of these drugs (51), but has been shown to be an important factor
influencing DHEA's effects on the immune system (101). The fact that the C. parvum
infection was chronic prior to DHEA treatment is also a reasonable hypothesis explaining
the lack of parasite reduction following oral therapeutic administration. Utilizing DHEA
in a prophylactic manner may prove to be more effective against C. parvum infection (2).
Based on more recent findings in our laboratory (unpublished data), it is
recommended that the DHEA administered orally be given at a concentration several fold
greater than the dose administered in the present study. The mice given oral DHEA may
have received too low of a dose to enable any reversal of the effects on the immune
system caused by the DEX-immunosuppression.
Subcutaneous administration of DHEA and DHEAS also failed to show any
significant reductions in infection with C. parvum. Decreased cryptosporidial activity in
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rats and hamsters has been associated with DHEA administered subcutaneously (93, 94).
Moreover, DHEA and DHEAS given subcutaneously have yielded significant increases
in humoral and CMI responses as well as increased lymphokine production in rodents
(36, 37, 94). In AIDS patients, circulating levels of DHEA and DHEAS are suppressed
while GC levels are elevated (42, 78). Dehydroepiandrosterone is presently undergoing
evaluatio n for treatment of AIDS patients and has had minimal side effects (42) .
Numerous reports continue to support the use of DHEA and DHEAS as agents for
potentiating the immune respon se against opportunistic infections such as
cryptosporidiosis.
As indicated by the spleen weights in Table 10, some doses of DHEA and DHEAS
appeared to be boosting the immune system of the mice. Mice receiving DHEA
administered orally had spleen weights comparable to controls.

Subcutaneous

administration of DHEA at 6 mg (group-3b) and DHEAS at 3 mg (group-4a) resulted in
spleen weights significantly (P :!> 0.05) higher than control mice. Although secondary
infections were not observed in mice from groups-3b and 4a, it is possible that their
higher spleen weights resulted from an undetected secondary infection. The mice in
group-3b and group-4a survived longer than the mice with lower spleen weights that
were receiving the same DHEA or DHEAS regimen at a different dose (e.g., those mice
in the same group but different subgroup). This finding suggests that the spleen weights
may have a correlation to the overall health of the mice. The body weights (Table 10)
gave very little indication as to the health of the mice. All but one group had body
weights comparable to the controls, which further suggests that the doses of DHEA and
DHEAS administered in these experiments were not high enough to elicit a significant
reduction in cryptosporidial infection .
Since this study was completed, follow -up experiments in our lab have utilized the
results of the present study to determine an optimal dose for DHEA in mice. These
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follow-up results concluded that a higher dose of DJ·IEA and a different dosing regimen
induced more profound effects on decreasing cryptosporidial activity (unpublished data).
Because of the apparent association between GC, stress, and disease, evidence
suggests that DHEA can enhance the ability of the immune system to guard against GCinduced immunosuppression and pathogen-induced illness (67, 100). Utilizing the
C57BL/6N mouse as a model to determine the efficacy of DHEA and other
immunomodulators against cryptosporidiosis deserves further investigation.
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